UC San Diego
Research Theses and Dissertations

Title
Anticancer Compounds from Marine Invertebrates

Permalink
https://escholarship.org/uc/item/1xk3x815

Author
Sandler, Joel S.

Publication Date
2005

Peer reviewed
UNIVERSITY OF CALIFORNIA, SAN DIEGO

SCRIPPS INSTITUTION OF OCEANOGRAPHY

Anticancer Compounds from Marine Invertebrates

A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Oceanography

by

Joel Stuart Sandler

Committee in charge

Professor William H. Fenical, Chair
Professor Lihini L. Aluwihare
Professor Douglas H. Bartlett
Professor Katherine A. Barbeau
Professor Emmanuel Theodorakis

2005
INFORMATION TO USERS

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.
The dissertation of Joel Stuart Sandler is approved, and it is acceptable in quality and form for publication on microfilm:

[Signatures]

Chair

University of California, San Diego

2005
To Mom and Dad,
for giving me the imagination to dream the impossible
and the means of attaining it.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature Page</td>
<td>iii</td>
</tr>
<tr>
<td>Dedication</td>
<td>iv</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>v</td>
</tr>
<tr>
<td>List of Abbreviations</td>
<td>vi</td>
</tr>
<tr>
<td>List of Tables and Figures</td>
<td>ix</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>xii</td>
</tr>
<tr>
<td>Vita, Publications, and Fields of Study</td>
<td>xvii</td>
</tr>
<tr>
<td>Abstract</td>
<td>xviii</td>
</tr>
<tr>
<td>Chapter 1 Introduction: Anticancer Compounds from Marine Invertebrates</td>
<td>1</td>
</tr>
<tr>
<td>Chapter 2 Cytotoxic β-Carbolines and Cyclic Peroxides from the Palauan Sponge Plakortis nigra</td>
<td>39</td>
</tr>
<tr>
<td>Chapter 3 Erylosides A, K, and L: Bioactive Steroidal Glycosides from the Marine Sponge Erylus lendenfeldi</td>
<td>73</td>
</tr>
<tr>
<td>Chapter 4 Novel Macrolides from a New Deep-water Palauan Sponge Leiodermatium sp.</td>
<td>118</td>
</tr>
</tbody>
</table>
LIST OF ABBREVIATIONS

[α]D \hspace{1cm} \text{optical rotation}

δ/δH/δC \hspace{1cm} \text{NMR chemical shift/ proton shift/ carbon shift}

Δ \hspace{1cm} \text{double bond or genetic deletion}

ΔδS,R \hspace{1cm} \text{delta-delta value (Mosher's method)}

ε \hspace{1cm} \text{epsilon value (indicates intensity of ultraviolet absorption)}

λmax \hspace{1cm} \text{ultraviolet wavelength maximum}

νmax \hspace{1cm} \text{infrared wavelength maximum}

[θ] \hspace{1cm} \text{circular dichroism rotation}

1H \hspace{1cm} \text{proton}

13C \hspace{1cm} \text{carbon-13}

CD \hspace{1cm} \text{circular dichroism}

CDCl3 \hspace{1cm} \text{deuterated chloroform}

COSY \hspace{1cm} \text{correlation spectroscopy}

DMSO-d6 \hspace{1cm} \text{deuterated dimethyl sulfoxide}

DSB \hspace{1cm} \text{double strand break}

EIMS \hspace{1cm} \text{electron ionization mass spectrometry}

ESI \hspace{1cm} \text{electrospray ionization mass spectrometry}

EtOAc \hspace{1cm} \text{ethyl acetate}

FABMS \hspace{1cm} \text{fast atom bombardment mass spectrometry}

FACS \hspace{1cm} \text{fluorescence activated cell sorting}
FDA  Food and Drug Administration
HCl  hydrochloric acid
HCT-116  human colon tumor cell line 116
HMBC/gHMBC  heteronuclear multiple-bond correlation/ gradient HMBC
HPLC  high performance liquid chromatography
IC$_{50}$  concentration at which 50% survival is observed
MALDI  matrix assisted laser desorption mass spectrometry
HR  high-resolution
HSQC/gHSQC  heteronuclear single-quantum correlation/ gradient HSQC
HSQMBC  heteronuclear single quantum multiple bond correlation
IR  infrared
$J$  coupling constant
[M+H]$^+$  protonated molecular ion
$m/z$  mass to charge ratio
MeOH-$d_4$  deuterated methanol
MTPA/MTPACl  methoxy trifluoromethyl phenyl acetate/ MTPA acid chloride
NCI  National Cancer Institute
NMR  nuclear magnetic resonance
NOE/NOESY  nuclear Overhauser effect/ NOE spectroscopy
OD$_{600}$  optical density at 600 nm wavelength
ROESY  rotational NOE spectroscopy
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOCSY</td>
<td>total correlation spectroscopy</td>
</tr>
<tr>
<td>TOP1/topo I</td>
<td>topoisomerase 1</td>
</tr>
<tr>
<td>TOP2/topo II</td>
<td>topoisomerase 2</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
</tbody>
</table>
# LIST OF TABLES AND FIGURES

## CHAPTER 1

| Table 1.1 Biological activity of anticancer marine natural products | 28 |

## CHAPTER 2

| Figure 2.1 UV spectrum for plakortamine A (1) | 47 |
| Figure 2.2 Enlargement of the HMBC spectrum for plakortamine A (1) | 48 |
| Figure 2.3 Positive (top) and negative (bottom) electrospray ionization mass spectra for plakortamine B (2) | 50 |
| Figure 2.4 $^{13}$C NMR spectrum for plakortamine B (2) in MeOH-$d_4$ | 51 |
| Figure 2.5 Annotated $^1$H NMR spectrum for plakortamine B (2) in CDCl$_3$ | 52 |
| Figure 2.6 Biosynthetic mechanism for the formation of the β-carboline skeleton of the plakortamines | 53 |
| Figure 2.7 $^{13}$C NMR spectrum for epiplakinic acid G (5) in MeOH-$d_4$ | 55 |
| Figure 2.8 $^1$H NMR spectrum for epiplakinic acid G (5) in CDCl$_3$ | 56 |
| Figure 2.9 1D-NOESY correlations (dashed arcs) for cyclic peroxide portion of epiplakinic acid G (5) | 58 |
| Figure 2.10 Comparison of the upfield region of the $^1$H NMR spectra for 7 (top) and 8 (bottom) | 60 |
| Figure 2.11 Dose-response curve of human cancer cells (HCT-116) exposed to compounds 1, 2, and 4 | 62 |
CHAPTER 3

Table 3.1 $^{13}$C (100 MHz, MeOH-$d_4$) and $^1$H (300 MHz, MeOH-$d_4$) NMR data for compounds 1 and 3.......................... 83

Figure 3.1 Distribution of $\Delta\delta_{S-R}$ values (Hz) for the MTPA esters of 19..... 84

Table 3.2 $^{13}$C (100 MHz, MeOH-$d_4$), $^1$H (300 MHz, MeOH-$d_4$), and HMBC (300 MHz, MeOH-$d_4$) NMR data for compound 2.......................... 86

Figure 3.2 Enlargement of the upfield region of the HSQC spectra for compounds (a) 1, (b) 2, and (c) 3.......................... 88

Figure 3.3 Comparison of the downfield region of $^{13}$C NMR spectra for 1 (top) and 2 (bottom).......................... 89

Figure 3.4 NOE correlations for the steroidal portion of 2.......................... 91

Figure 3.5 Catalytic hydrogenation of 1 and 2.......................... 94

Figure 3.6 HPLC chromatograms of hydrogenation products from (a) 1 and (b) 2.......................... 95

Table 3.3 Activity of erylosides and some reference topoisomerase poisons against different yeast strains.......................... 96

Figure 3.7 Effect of compound 1 on cell cycle of wild type yeast............. 99

Figure 3.8 Effects of compounds 1-3 on (a) topoisomerase I and (b) topoisomerase II.......................... 100

Table 3.4 Results from COMPARE analysis of compounds 1-3............. 102

CHAPTER 4

Table 4.1 $^{13}$C (75 Mz, MeOH-$d_4$), $^1$H (500 Mz, MeOH-$d_4$), and HMBC (500 Mz, MeOH-$d_4$) NMR data for 1.......................... 128

Figure 4.1 $^1$H NMR spectrum for leiodelide A (1) in MeOH-$d_4$............. 129

Figure 4.2 $^{13}$C NMR spectrum for leiodelide A (1) in MeOH-$d_4$............. 130

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ACKNOWLEDGEMENTS

I am extremely grateful to everyone who has touched my life in the past five years as a graduate student. My tenure here has been very interesting, and I have learned more in this small amount of time than I had in the previous twenty years, both about myself and the natural world around me.

I must first thank the late John Faulkner, who served as my mentor and friend for three years before his untimely passing. It’s difficult to summarize the impact that John had and continues to have on me. I believe that he truly took a chance on me, and I would like to think that I have validated his decision. John was always patient with my capricious curiosities, to which he enjoyed responding “Let’s see how you feel about this project next week, shall we?” He was a scientist in the truest sense of the word, and I miss him dearly.

In addition to John, I have been fortunate to have two wonderful co-advisors who have influenced my approach to science and life. Susan Forsburg is a brilliant cell biologist who took a genuine interest in my dream to find novel and selective inhibitors of cell-cycle processes in yeast. It was always difficult to keep up with her, and I feel that I have become a better scientist by learning how to do so. Susan selflessly donated her time and resources to my cause, and she adopted me into her lab for nothing in return. Members of the Forsburg lab taught me how to approach a biological system with patience and exactitude.
I need to thank Bill Fenical, my second co-advisor, for many things.
When John passed away, Bill made sure that everyone in the Faulkner lab had a
home to continue their research without any hindrances or distractions. Without
Bill’s support, I would not be writing this today. Aside from this, Bill has served
as a mentor during the second half of my graduate career. He has forced me to
ask myself difficult questions about where I want to go and how I can get there.
Bill taught me how to how to continue driving straight when I hit a bump in the
road and finish what I’ve started.

My committee members have been very generous with their time and
insight. Lihini Aluwihare is an enthusiastic and sympathetic scientist, and she is a
good friend. She provided help with GC studies that were not mentioned in this
thesis. Doug Bartlett has a genuine interest in all different kinds of scientific
problems. His questions are remarkably pertinent and I have always enjoyed our
meetings. I would like to thank the late Murray Goodman for sitting on my
committee. He was an accomplished and demanding chemist who will be greatly
missed. I am grateful to Emmanuel Theodorakis for agreeing to sit on my
committee and for providing feedback on some of my stereochemistry problems.
His student, Fatima Rivas, provided help with ozonolysis studies that were not
mentioned in this thesis. I also thank Kathy Barbeau for serving on my
committee.

Catherine Sincich was instrumental in keeping the Faulkner lab together
after John left us. She was tireless in her devotion to keeping everything running
flawlessly and I thank her for that. Above all, I thank her for saving my life (literally) in Palau. James Laclair has been an interesting collaborator and I have always enjoyed our discussions. We worked together on several fluorescence studies that are not mentioned in this thesis. Jim has shown me how to question everything, including conventional science and convention in general. Evelyn York has done a great job keeping the NMR instruments running, and she was always fun to talk with. Pat and Lori Colin at the Coral Reef Research Foundation have been very generous with accommodations and other resources in Palau.

Students and postdocs at SIO have been instrumental in teaching me how to be a scientist. Marcus Huebes and Lyndon West are two postdocs who first taught me how to purify and characterize marine natural products. Christine Blackburn is an excellent scientist who helped inspire me in my first year at SIO. It is because of Chris that I am currently interested in chemical biology. Christine Salomon is an extremely enthusiastic person who taught me to have fun with my research. Christian Ridley is a great chemist, and I am indebted to him for many of my good decisions as a scientist. I thank Wendy Strangman for her friendship and delectable desserts. In my latter years at SIO, postdocs Philip Williams, Chambers Hughes, John Macmillan, and Han Kwon have been very helpful in forcing me to challenge myself as a chemist. They are all amazing chemists that I have been fortunate to work with. I thank the rest of the Faulkner lab and Fenical
lab for working with me and providing great feedback at seminars and chalk talks.

I would never have been able to complete this thesis without the love and support of my family. My dad taught me how to work hard and stay focused. His life is a model that I aspire towards, both in work and play. My mom taught me how to overcome adversity with a smile, and she raised me to be a mensch. My brother Ian always told me that whatever I choose to do, make sure I do it well. My brand new niece Riley has given me the impetus to finish this thing and go back to New York. Finally, I thank Michelle, my true love and friend forever. Michelle always knows how to make me laugh and take life less seriously. And her countless late night hours spent in the lab with me entitles her to a piece of this degree.

* * *

Chapter 2 acknowledgements: Collection of the sponge material was made by Patrick Colin of the Coral Reef Research Foundation. The sponge was identified by John Hooper. Ralf Goericke allowed me to work on his Finnigan LCQ mass spectrometer. We thank the Republic of Palau for providing collection permits and the Coral Reef Research Foundation for logistical support.

* * *

Chapter 3 acknowledgements: This work is the result of a collaboration with Susan Forsburg, who is a co-author. Collection of the sponge material was made by Grace Lim, Melissa Lerch, Christine Blackburn, and Christine Salomon.
Lou Barrows and Kathryn Marshall at the University of Utah performed the DNA cleavage assays.

* * *

Chapter 4 acknowledgements: Collection of the sponge material was made by Patrick Colin of the Coral Reef Research Foundation. We thank the National Cancer Institute for generously providing the sponge material. The sponge was identified by Michelle Kelly.

* * *

Funding for this research was provided by the California Sea Grant College Program and the National Institutes of Health. I also thank the ARCS San Diego foundation for a fellowship that supported my graduate work.
VITA

July 1, 1977 Born, Dix Hills, NY
June, 1999 B.A., Cornell University, Ithaca, NY
2000-2005 Graduate student researcher, University of California, San Diego
2005 Ph.D., University of California, San Diego

PUBLICATIONS


FIELDS OF STUDY

Major Field: Marine Chemistry

Studies in Marine Natural Products Chemistry
Professors D. John Faulkner and William H. Fenical
Scripps Institution of Oceanography

Studies in Cell Biology and Genetics
Professor Susan L. Forsburg, Salk Institute for Biological Studies
ABSTRACT OF THE DISSERTATION

Anticancer Compounds from Marine Invertebrates

by

Joel Stuart Sandler

Doctor of Philosophy in Oceanography

University of California, San Diego, 2005

Professor William H. Fenical, Chair

For more than thirty years, marine natural products chemists have studied sponges, ascidians, and other marine invertebrates because of their ability to produce secondary metabolites with unique chemical structures and potent bioactivities. The remarkable abundance and diversity of bioactive small molecules that have been isolated from marine invertebrates have made these organisms an important source of new drug candidates for human diseases, particularly in the fight against cancer. As a result, there are now a number of marine natural products in clinical or preclinical trials for the treatment of different kinds of cancer.
The objective of this thesis is to describe the isolation and characterization of novel anticancer compounds from marine invertebrates. Each chapter discusses dramatically different types of molecules that have been identified in marine sponges, linked only by the fact that they all demonstrate activity on a cancer or cancer-related assay. The first chapter provides an overview of the various anticancer compounds that have been isolated from marine invertebrates, with particular emphasis on the specific bioactivities demonstrated by each compound. Chapter 2 provides a report of several interesting series of molecules isolated from a single Palauan sponge. The techniques used towards the isolation and structural elucidation of organic compounds, including HPLC, NMR, and mass spectrometry, are presented here before being elaborated upon in subsequent chapters. In chapter 3, a series of compounds are isolated from a Red Sea sponge based on their activity in an assay designed to identify novel cell-cycle inhibitors. In addition to a report of the isolation and structural elucidation of these compounds, this chapter also describes several studies aimed at further characterizing their bioactivity. Chapter 4 presents two completely novel compounds isolated from a new deep-water sponge. Several interesting techniques were employed to develop a model of the relative stereochemistry of neighboring chiral centers within each molecule. Ultimately, a story is told of the challenges and solutions involved in purifying and characterizing marine invertebrate natural products.
CHAPTER 1

INTRODUCTION: ANTICANCER COMPOUNDS
FROM MARINE INVERTEBRATES

The oceans cover roughly three-quarters of Earth’s surface, and some marine ecosystems, such as coral reefs and deep-sea hydrothermal vents, exhibit biological diversity that rivals that found in any of the other ecosystems in the known universe. Marine invertebrates comprise an important part of many of these ecosystems. These organisms are soft-bodied and, in some cases, sessile, making them physically vulnerable to predation, microbial fouling, and competition for resources. As a result, they have evolved the ability to synthesize toxic compounds as a means of defense. Upon being released into the water, these natural products are rapidly diluted and therefore need to be highly potent to be effective.

A large number of bioactive marine natural products have been discovered in the quest for new drugs to treat human diseases. Marine invertebrates have provided a large proportion of bioactive natural products reported in the past 30 years,¹ and an ever-expanding access to new marine habitats ensures that this resource has not yet been exhausted. In particular, many bioactive natural products have been isolated in the search for new drugs to treat various types of
cancer. This chapter reviews the role of marine invertebrate natural products with respect to the discovery and development of different forms of cancer treatment.

A Brief History of Cancer Treatment

Cancer and its various remedies have been described since the earliest medical records were kept. Ancient Egyptian papyri contain descriptions of surgery and pharmacological treatments of cancer dating from sources as early as 2500 B.C. During the Renaissance, cancer was considered incurable, although a wide variety of pastes containing arsenic were compounded to treat its manifestations. Surgical techniques progressed in the 17th century thanks to the work of renowned practitioners such as Fabricius Hildanus, Johann Scultetus, and Marco Severinus. It wasn’t until the 19th century, however, with the invention and use of the modern microscope, that scientific oncology truly began. Rudolf Virchow, often called the founder of cellular pathology, provided the scientific basis for the modern study of cancer. It was Virchow who first correlated microscopic observations of cancer cells with the clinical course of illness. At the same time, surgeons such as William Stewart Halsted and W. Sampson Handley were pioneering radical mastectomy procedures. Stephen Paget, an English surgeon, suggested that cancer cells spread by way of the bloodstream to all organs, thereby delineating the concept of metastasis almost 100 years before the hypothesis could be confirmed by modern cellular and molecular biology.
In 1901, German physics professor Wilhelm Conrad Roentgen generated global excitement with his characterization of the X-ray. Within 3 years of its discovery, radiation was used in the treatment of cancer. A major breakthrough took place in France when it was discovered that daily doses of radiation over several weeks would greatly improve therapeutic response. The methods and the machines for delivery of radiation therapy steadily improved, and it can now be delivered with great precision in order to destroy malignant tumors while minimizing damage to adjacent normal tissue.

While physical methods, such as surgery and radiation, are invaluable measures for slowing or reversing the effects of cancer, chemical intervention provides a potentially less invasive and more effective solution. During World War II, the U.S Army was studying a number of compounds related to mustard gas in order to develop more effective chemical warfare agents. In the course of that work, nitrogen mustard (I) was found to have substantial activity in lymphoma patients. This compound served as the model for a series of more effective analogs that killed rapidly proliferating cancer cells. Soon afterwards, Sidney Farber demonstrated that aminopterin (2), an analog of folic acid, produced remission in child leukemia patients. Aminopterin, which blocked a critical chemical reaction needed for DNA replication, was the predecessor of methotrexate (3), a cancer drug commonly used today. The first cure of metastatic cancer was reported in 1956 when methotrexate was used to treat a rare
tumor called choriocarcinoma, thereby demonstrating the importance of chemotherapy in cancer treatment.

Since the discovery and implementation of these early drugs, researchers have uncovered numerous compounds that are used for cancer chemotherapy. While many of these compounds effectively inhibited cancer cell growth, they often displayed non-selective cytotoxicity in patients due to the molecular similarities between cancerous and healthy human cells. The discovery of selective anticancer drugs is now becoming more prevalent due to the advent of
molecular genetics combined with improved assay technology and remarkable advances in organic chemistry.9

**Modern Drug Discovery**

In 1953, James Watson and Francis Crick reported the chemical structure of DNA, the building block of genetic material found in all living organisms.10 Researchers soon discovered that genes contained the information required for cellular structure and function and that this information was passed down with each cell division. Furthermore, genetic abnormalities did not always result in cell death and could persist from one generation to the next, often in association with cancer. Traditional genetic approaches combined with new genomics technologies have subsequently revealed an abundance of “oncogenes” whose aberrant function is implicated in different types of cancer.11,12

Most of the current strategies for finding new anticancer drugs rely on the discovery of compounds that target the subtle molecular differences between malignant and healthy human cells. Certain genetic defects render cancer cells sensitive to particular compounds, and many pathways represent potential chemotherapeutic targets to be exploited by drugs.13 Countless assays are currently employed to find compounds that inhibit almost all of the known cancer-related proteins or pathways. When such assays are automated, it becomes possible to screen huge libraries of compounds in a routine manner, thereby increasing the likelihood of identifying specific inhibitors.
Large chemical libraries are typically generated from either combinatorial chemistry methods or natural product extracts. Combinatorial chemistry is a technology in which different chemical precursors are repeatedly pooled together and exposed to common synthetic conditions, thereby creating large numbers of diverse molecules *en mass*. Rapid screening of the resulting libraries has the benefit of providing a large amount of data in a relatively short period of time. This method has several shortcomings, however, including the inability of existing chemical libraries to occupy diverse regions of biochemical space and the presence of nuisance compounds that generate false positives or non-specific hits in pure-protein assays.

An alternative approach to generating large chemical libraries involves the collection and extraction of organisms that are known to produce bioactive secondary metabolites. Terrestrial plants, microbes, and invertebrates have provided man with countless natural remedies for thousands of years. These organisms contain bioactive secondary metabolites that have enabled them to communicate, compete for resources, and defend against predators. Although secondary metabolites do not always exhibit biomedical activity, similarities between the biological targets (i.e. proteins, organelles, DNA) against which these compounds have evolved and the biomedical targets involved in human pathogenesis explain how certain natural products can be used to combat diseases.

Medicinal chemists have been interested in secondary metabolites for hundreds of years. Until recently, however, the purification and characterization
of complex natural products had been an arduous task. Dramatic improvements in analytical technologies, such as high-pressure liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and mass spectroscopy, have greatly facilitated this process. The discovery and characterization of natural anticancer drugs such as vinblastine (4) and vincristine (5),\textsuperscript{17} etoposide (6),\textsuperscript{18} and Taxol (7)\textsuperscript{19} from plants, and the bleomycins (8, bleomycin A),\textsuperscript{20} mitomycin C (9),\textsuperscript{21} doxorubicin (10),\textsuperscript{22} and the epothilones (11, epothilone A)\textsuperscript{23} from microbes, have illustrated the importance of bioactive secondary metabolites in the clinic.\textsuperscript{24} In addition to terrestrial plants and microbes, marine organisms have recently become a fruitful resource for new anticancer compounds.

**Anticancer Compounds from Marine Invertebrates**

Until the mid-1960s, investigations of natural products from marine organisms was essentially non-existent. The modernization of scuba technology in the seventies and eighties resulted in accessibility to previously unexplored marine ecosystems. Since then, close to 20,000 new compounds have been reported from marine microbes, seaweeds, and invertebrates.\textsuperscript{1,25} Marine invertebrates have proven to be a particularly rich source of novel anticancer compounds. Despite the fact that no marine-derived compounds have been licensed for clinical use as anticancer drugs, at least ten compounds are in various stages of formal testing and many more are undergoing preclinical evaluation.\textsuperscript{26}
The following is a discussion of selected marine invertebrate natural products that have been investigated as potential anticancer drugs. Particular emphasis is placed on the biochemical pathways targeted by these compounds that result in their selective anticancer activity. By necessity, certain important examples are omitted, particularly in cases where a large number of molecules have been shown to inhibit the same target. Rather than providing a comprehensive review, the goal here is to emphasize the extraordinary range of cancer-related pathways targeted by marine natural products. The clinical activity of anticancer marine natural products has already been detailed in several excellent reviews,\textsuperscript{27-29} and will therefore not be discussed here.

I. Microtubule stabilization

Actively dividing cells undergo a process, known as mitosis, in which two identical copies of the cell's genetic material are equally distributed between the two nascent daughter cells. The chromosomes align along the central axis of the parent cell before each copy is pulled pole-ward by the spindle microtubules. Defects in microtubule regulation are implicated in the generation of chromosomal instability and aneuploidy, which are hallmarks of many types of cancers.\textsuperscript{30} Paclitaxel (Taxol\textsuperscript{TM})(7), one of the best-selling anticancer drugs and a standard against which many new drugs are evaluated,\textsuperscript{31} acts by stabilizing microtubules during cell-division. As a result, it selectively targets actively dividing cancer cells.\textsuperscript{32} Following the discovery of paclitaxel, several compounds
were isolated from marine invertebrates with similar bioactivity. Discodermolide (12), which was obtained from the Bahamian deep-water sponge Discodermia dissoluta, was initially described as a cytotoxic immunosuppressive agent. Subsequent work showed that 12 stabilized microtubules with greater potency than paclitaxel. Eleutherobin (13), a diterpene glycoside, was isolated from a rare acyonacean soft coral in Western Australia. Eleutherobin and its analogs, such as sarcodictyin A (14) were also shown to mimic the activity of paclitaxel by stabilizing microtubules.

II. Tubulin depolymerization

In addition to microtubule stabilizing agents, there is a class of compounds that causes the depolymerization of microtubules. The first compounds that were shown to possess this kind of activity were the vinca alkaloids, such as vinblastine (4) and vincristine (5). Since the discovery of these compounds, a handful of potent anticancer agents have been shown to bind to the “vinca” tubulin domain. The dolastatins, exemplified by dolastatin 10 (15), are linear peptides that were originally isolated in low yield from the sea hare Dolabella auricularia. Dolastatin 10 is a member of another series of linear peptides that have been isolated from several species of marine sponge. Both the dolastatins and the hemiasterlins were shown to inhibit tubulin polymerization, with dolastatin 10 exhibiting the most potent activity. Spongistatin (17), a macrocyclic polyether lactone from an Eastern Indian Ocean Spongia species, was isolated based on its
extremely potent antitumor activity.\textsuperscript{42} Bai \textit{et al.} showed that 17 was a non-competitive inhibitor of tubulin binding against radiolabeled vinblastine and radiolabeled dolastatin 10.\textsuperscript{43} Since dolastatin 10 is also a non-competitive inhibitor, this finding implied the presence of at least three distinct binding sites in the vinca domain and helped to illustrate its complexity.

\section*{III. Actin depolymerization}

The actin cytoskeleton mediates a variety of essential biological functions in all eukaryotic cells. In addition to providing a structural framework around which cell shape and polarity are defined, the dynamic properties of actin provide the driving force for cells to move and to divide.\textsuperscript{44} Like microtubules, the different forms of actin play important roles in mitosis, cell signaling, and motility, making them the target of a growing number of anticancer drugs.\textsuperscript{45} Several marine natural products target the various forms of actin, and these compounds are important both as potential anticancer drugs and as biological tools to learn more about actin function. In 1999, Cuadros \textit{et al.} reported the discovery of spisulosine (18), a hydroxyamino alkane from the marine clam \textit{Spisula polynyma}.\textsuperscript{46} Cells treated with 18 exhibited a decreased capacity for cellular adhesion, indicating that the compound prevented the formation of actin stress fibers. These fibers are controlled by the presence and activation of the small GTP-binding Rho proteins.\textsuperscript{47} Spisulosine somewhat resembles the
endogenous Rho-modulating compound lysophosphatidic acid (LPA) and may act by competitively binding to and inhibiting the LPA receptor. Latrunculins A (19) and B (20), potent cytotoxins isolated from the Red Sea sponge Latrunculia magnifica, induced striking changes in cell morphology that were shown by immunofluorescence to be caused by an alteration in the organization of actin microfilaments.\textsuperscript{48, 49} Coue \textit{et al.} demonstrated that latrunculin A inhibits the polymerization of actin \textit{in vitro},\textsuperscript{50} and the latrunculins have since been used as molecular probes to investigate the biochemical roles of actin. Several other cytotoxic marine macrolides, such as swinholide A, scytophycin C, and mycalolide A, selectively inhibit actin and have been used as molecular probes.\textsuperscript{51}

IV. DNA alkylation

Since the introduction of the nitrogen mustard (1) over fifty years ago, DNA alkylating agents have played a major role in cancer chemotherapy. These compounds tend to possess a reactive functional group that allows them to bind to DNA, resulting in damage and cell death.\textsuperscript{52} The ecteinascidins are a series of amino acid-derived alkaloids isolated from the Caribbean ascidian \textit{Ecteinascidia turbinata}.\textsuperscript{53} The dominant metabolite, ecteinascidin 743 (21), exhibited potent activity against a variety of tumor cells. Pommier \textit{et al.} directly showed that 21 was a DNA-alkylating agent.\textsuperscript{54} Specifically, the carbinolamine center at the N2 position of 21 formed a Schiff base upon elimination of the adjacent alcohol,
which was subject to nucleophilic attack by nitrogen from guanine residues in the DNA minor-groove. The resulting ecteinascidin-DNA linkage was irreversible and caused the DNA helix to bend.

V. DNA cleavage

Topoisomerasases I and II are enzymes that bind to double-stranded DNA and cause transient single-stranded (type I) or double-stranded (type II) breaks that are essential for uncoiling of the DNA helix during replication and transcription. Both types of topoisomerasases are overexpressed in cancer cells, making them important chemotherapeutic targets. A class of anticancer compounds, known as topoisomerase inhibitors, are capable of cleaving DNA by covalently binding the DNA-topoisomerase complex and preventing resealing of DNA after it has been cleaved by the enzyme. Ascididemin (22), a pyridoacridine alkaloid from the Okinawan tunicate Didemnum sp., was shown to exhibit potent DNA cleavage activity. Further studies have linked this activity with the inhibition of topoisomerase II. In addition, work by Ireland’s group showed that other pyridoacridines also cleaved DNA, and that this activity was due to an ability to inhibit topoisomerase II catalytic activity.

VI. Protein kinase C activation

Protein kinases mediate the majority of signal transduction in eukaryotic cells. In doing so, they control many cellular processes, such as transcription,
apoptosis, and cell cycle progression. Many types of cancers feature abnormal protein kinase activity, making these enzymes attractive targets for anticancer drug development. The molecular heterogeneity of protein kinase C (PKC) isozymes and their functional divergence have drawn a lot of attention by medicinal chemists as potential drug targets. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. Bryostatin 1 (23) is a macrocyclic lactone from the bryozoan Bugula neritina. Compound 23 showed potent in vivo antitumor activity and is being investigated as an anticancer drug. Mechanistic studies have shown that 23 was able to outcompete the tumor-promoting phorbol esters for binding to calcium phospholipid-dependent PKC. In the absence of bryostatin 1, the phorbol esters bind to and activate PKC, resulting in the differentiation and proliferation of certain types of cancers.

Compound 23 also activates PKC upon binding, but it does not promote tumor-cell proliferation. Bryostatin 1 is currently being tested in combination with other cancer drugs.

VII. Methionine Aminopeptidase inhibition

Methionine aminopeptidases (MetAPs) catalyze the removal of the initiator methionine residue in newly synthesized proteins. Inhibitors of MetAPs have been shown to exhibit selective activity against endothelial cells, despite a lack of differential expression or upregulation of MetAP in these cell types.
ability of fumagillin (24), a fungal metabolite, to selectively target MetAP2 leads to an inhibition of angiogenesis (formation of blood vessels), which is necessary for the survival of tumor cells. Bengamides A (25) and B (26) were originally isolated from a marine sponge Jaspis sp. Bengamide B, which caused inhibition of human tumor cells at low nanomolar concentrations, was one of the most potent members of the class. Although 26 was an attractive drug candidate, its limited availability from natural sources and poor solubility prevented further development of the therapeutic agent. LAF389 (27), a synthetic bengamide analog, showed in vitro activity equivalent to 26 against a broad panel of human tumor cell lines and improved activity in human tumor xenograft models. After many failed attempts to identify the molecular target of the bengamides, including tests in a number of enzymatic assays and the National Cancer Institute 60-cell line panel, a proteomics approach was undertaken to show that the bengamides inhibited MetAPs. Unlike previously reported MetAP inhibitors, however, the bengamides were non-selective against various cell lines and did not block angiogenesis.

VIII. ATPase inhibition

ATPase enzymes are responsible for generating electrochemical gradients in eukaryotic cells by pumping ions across cellular or organelle membranes. The differential regulation of ATPases in various cell types suggests that their inhibition could be therapeutically advantageous. Vacuolar-ATPase (V-
ATPase) has been proposed as a drug target in osteoporosis due to its involvement in bone resorption, and as a target in cancer due to potential involvement in tumor invasion and metastasis. Many of the known selective inhibitors of V-ATPase, however, have proven to be too toxic for therapeutic use. Salicylihalamides A (28) and B (29) are potent macrolides that were isolated from a Western Australian sponge Haliclona sp. The compounds were screened in the the NCI 60-cell line human tumor assay and showed similar activity profiles with known V-ATPase inhibitors. Subsequent work resulted in the isolation of several more bioactive analogs that were directly shown to inhibit V-ATPase function.

IX. Telomerase inhibition

Telomeres, the structure at the ends of linear chromosomes, have long been recognized as critical for the maintenance of chromosomal integrity. Telomerase is a ribonucleoprotein enzyme that adds telomeres onto the 3'-ends of chromosomes. While telomerase activity is found in about 90% of human tumors, the enzyme is somewhat quiescent in normal cells, suggesting that telomerase inhibitors might display good selectivity against tumor cells. The validity of telomerase as a drug target has been shown by several telomerase inhibitors that have been successful in clinical trials. In an effort to find anti-telomerase marine natural products, Warabi et al. investigated the Japanese marine sponge Dictyodendrilla verongiformis. Bioassay-guided fractionation led to the isolation of the dictyodendrins (30, dictyodendrin C), which displayed
complete inhibition of human telomerase at 50 μg/ml. The desulfated analog 31, which was obtained by acid hydrolysis of 30, exhibited no telomerase inhibitory activity, demonstrating the necessity of a sulfate ester moiety for activity.

X. Cyclin-dependent kinase inhibition

The cyclin-dependent kinases (CDKs) are responsible for phosphorylating various substrates that are critical to cell-cycle progression. The levels of CDKs are invariant throughout the cell cycle, but their activities are modulated by interactions with cyclins, whose levels fluctuate with the cell cycle. The presence of a CDK-cyclin complex allows the cell cycle to progress. However, endogenous CDK inhibitors can bind to the complex and cause cell-cycle arrest, suggesting the presence of binding sites that can be exploited by selective inhibitors. Cancer cells are generally characterized by a loss of cell-cycle regulation, aberrant expression of CDKs or cyclins, and the loss or mutation of native CDK inhibitors. Because cyclin levels can vary dramatically between normal and cancerous cells, compounds that target specific CDKs or CDK-cyclin complexes are highly sought after as anticancer drugs. Indeed, selective CDK-inhibitors have shown promise in cancer clinical trials. Fascaplysin (32), an indole-containing pigment from the Fijian sponge Fascaplysinopsis sp., was originally reported with antimicrobial and cytotoxic properties. In a subsequent search for CDK inhibitors, Soni et al. observed that 32 inhibited CDK4 activity
with an IC\textsubscript{50} = 0.35 \mu M. Molecular modeling showed that the compound, which caused G\textsubscript{1} arrest in several types of cancer cells, occupied the ATP binding pocket of CDK4. Variolins A (33) and B (34), cytotoxic pyridopyrrolopyrimidine alkaloids isolated from the Antarctic sponge \textit{Kirkpatrickia variolosa},\textsuperscript{85,86} exhibited nanomolar activity against a variety of cancer cell lines. These compounds were also shown to block the \textit{in vitro} kinase activity of at least three different CDK-cyclin complexes.\textsuperscript{87}

XI. Lysosome inhibition

Two major pathways for the degradation of proteins have been described: cytosolic degradation by the proteasome and autophagic degradation of proteins and organelles within the lysosome. The proteasome is responsible for the regulated degradation of short-lived proteins involved in cell cycle control as well as proteins that participate in stress responses such as DNA damage-induced cell cycle arrest or adaptation to hypoxia.\textsuperscript{88} Autophagic degradation of cellular proteins by the lysosome has been demonstrated to be important in developmental/differentiative remodeling of cells, and is also required for the cellular adaptation to nutrient deprivation and the elimination of damaged organelles.\textsuperscript{89} A number of examples linking alterations in proteasomal protein degradation to the pathogenesis of cancer exist,\textsuperscript{90} and several proteasome inhibitors are being clinically evaluated.\textsuperscript{91} In contrast, alterations in the lysosome
have only recently been linked to the causation of cancer,\textsuperscript{92} and it has now become an attractive drug target. Kahalalide F (35) is a cyclic depsipeptide that was isolated from the ascoglossan mollusk \textit{Elysia refrueclus}.\textsuperscript{93} In the presence of 35, HeLa cells became swollen with enlarged vacuoles. The formation of these vacuoles was shown to be the consequence of changes in lysosomal membranes, suggesting that the anticancer activity of kahalalide F is linked to its ability to selectively target the vacuoles.\textsuperscript{94} The compound is currently being evaluated in clinical trials.

XII. Protein synthesis inhibition

In most eukaryotes, two distinct GTP-dependent elongation factors (eEF1 and eEF2) are required for protein translation. eEF1 mediates the binding of aminoacylated tRNA to the A-site of the ribosome and its subsequent release, whereas eEF2 catalyzes the translocation of peptidyl-tRNA from the A-site to the P-site. Protein elongation factors have been implicated in various types of cancers,\textsuperscript{95,96} making them attractive anticancer targets. Didemnins A (36) and B (37) belong to a class of highly cytotoxic cyclic depsipeptides that were originally isolated by Rinehart \textit{et al.} from the Caribbean ascidian \textit{Trididemnum solidum}.\textsuperscript{97} Didemnin B (37) was the first marine natural product to enter clinical trials as an anticancer drug, but the compound was ultimately determined to be too toxic for use. Compound 37 rapidly induces apoptosis\textsuperscript{98} and causes irreversible inhibition of protein biosynthesis.\textsuperscript{99} Mechanistically, didemnin B was shown to bind and
inhibit the human elongation factor eEF1A, blocking protein biosynthesis at the elongation stage.\textsuperscript{100,101} Although this compound was not successful in clinical trials, the closely related dehydrodidemnin B (38, Aplidine) is currently being tested.\textsuperscript{102}

Marine invertebrates have provided a large diversity of novel bioactive compounds. Within the context of treating cancer, marine natural products represent one of the latest burgeoning frontiers that promise to provide new cures or treatments that can complement existing remedies. The availability of secondary metabolites that selectively target such a wide array of molecular pathways (Table 1.1) suggests that the marine environment has imposed a unique set of constraints on its inhabitants, forcing them to adapt in order to protect themselves and survive. The sequencing of an ever-expanding number of different genomes has revealed an extraordinary level of conservation among proteins and cellular machinery, providing a link between the biological targets against which these compounds were originally designed and the biomedical targets that scientists hope to inhibit. Although many of the known species of marine invertebrates have already been analyzed for novel anticancer compounds, there remain a large number of organisms that have not been sampled, particularly those in the less accessible deeper waters. Clearly, there are many discoveries yet to be made.
Table 1.1 Biological activity of anticancer marine natural products.

<table>
<thead>
<tr>
<th>Target</th>
<th>Mechanism of action</th>
<th>Compound</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytoskeleton</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microtubule stabilization</td>
<td>Discodermolide (12)</td>
<td>33, 34</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eleutherobin (13)</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Tubulin depolymerization</td>
<td>Dolastatin 10 (15)</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemiasterlin (16)</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spongistatin (17)</td>
<td>42, 43</td>
</tr>
<tr>
<td></td>
<td>Actin depolymerization</td>
<td>Spisulosin (18)</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latrunculins (19, 20)</td>
<td>48, 49</td>
</tr>
<tr>
<td><strong>DNA</strong></td>
<td>DNA alkylation</td>
<td>Ecteinascidin 743 (21)</td>
<td>53, 54</td>
</tr>
<tr>
<td></td>
<td>DNA cleavage</td>
<td>Ascididemin (22)</td>
<td>57-60</td>
</tr>
<tr>
<td><strong>Enzymes</strong></td>
<td>Protein kinase activation</td>
<td>Bryostatin 1 (23)</td>
<td>64, 65</td>
</tr>
<tr>
<td></td>
<td>MetAP inhibition</td>
<td>Bengamides (25, 26)</td>
<td>69, 71</td>
</tr>
<tr>
<td></td>
<td>ATPase inhibition</td>
<td>Salicylihalimides (28, 29)</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Telomerase inhibition</td>
<td>Dictyodendrins (30)</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>Cyclin dependent kinase inhibition</td>
<td>Fascaplysin (32)</td>
<td>83, 84</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Variolins (33, 34)</td>
<td>85, 86</td>
</tr>
<tr>
<td><strong>Cellular Processes</strong></td>
<td>Lysosome inhibition</td>
<td>Kahalalide F (35)</td>
<td>93, 94</td>
</tr>
<tr>
<td></td>
<td>Protein synthesis inhibition</td>
<td>Didemnins (36, 37)</td>
<td>97, 101</td>
</tr>
</tbody>
</table>
References


by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochemical Pharmacology 60, 527-537.


CHAPTER 2

CYTOTOXIC β-CARBOLINES AND CYCLIC PEROXIDES
FROM THE PALAUAN SPONGE PLAKORTIS NIGRA*

Four β-carbolines, plakortamines A-D (1-4), two cyclic peroxides, epiplakinic acids G and H (5-6), and two related γ-lactones, (2S*,4R*)- and (2R*,4R*)-2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactones (7-8), were isolated from the deep-water sponge Plakortis nigra from Palau. The structures were established based mainly on 1D and 2D NMR data. Most of the metabolites inhibited the HCT-116 human colon tumor cell line, and the biological activity of several compounds is being investigated further using the NCI 60-cell line assay.

This work originally appeared in the Journal of Natural Products 2002, 65, 1258-61 with co-authors Patrick L. Colin, John N.A. Hooper, and D. John Faulkner. It has been rewritten here for continuity and so that my contribution be clarified.

Introduction

Bioactive indole alkaloids have been known for a long time and account for some of the earliest examples of natural products characterization by chemists.\(^1\) In particular, many compounds possessing a β-carboline skeleton (9) have been isolated, some of which with potent and/or selective anticancer activity. Simple β-carbolines, such as harmane (10), harmaline (11), and harmine (12), were originally isolated from the medicinal plant *Peganum harmala*,\(^2\) and have been shown to inhibit the human topoisomerase enzymes, which are important targets for anticancer chemotherapy.\(^3\) More recently, harmine derivatives were shown to be potent inducers of apoptosis in certain tumors.\(^4\) Extracts from the root of *Eurycoma harmandiana* have been used in Thai traditional medicine as an anticancer and antimalarial curative. Bioassay-guided fractionation of the root extract led to the isolation of the bioactive β-carboline alkaloids 13 and 14 that were responsible for the observed anticancer activity.\(^5\) Similarly, the β-carboline-benzoquinolizidine alkaloid deoxytubulosine (15) was isolated as the active component from the flowers of the Indian medicinal plant *Alangium lamarckii*.\(^6\) Several elegant studies conducted by Rao *et al.* showed that 15 inhibits the enzymatic activity of thymidylate synthase\(^7\) and dihydrofolate reductase,\(^8\) two attractive targets for the development of anticancer chemotherapeutic agents.

Simple marine-derived β-carbolines, such as those described in this chapter, are normally associated with ascidians\(^9\) and are exemplified by the
antiviral eudistomins from the Caribbean tunicate *Eudistoma olivaceum*. The majority of β-carboline analogs found in sponges belong to a more complex group of anticancer antibiotics known as the manzamines, such as manzamine A (16) and hydroxymanzamine A (17). More than thirty manzamine analogs have been isolated from several different sponge species, and the ubiquity of these compounds has led some to speculate that they may be produced by symbiotic microorganisms. In addition to the manzamines, a few simpler β-carboline analogs have been isolated from sponges.

Naturally-occurring cyclic peroxides account for the potent anticancer and antimalarial activity found in many species of medicinal plants and marine sponges. While the majority of sponge-derived peroxides contain six-membered rings, a few five-membered 1,2-dioxolane carboxylates have also been reported. The first example of a five-membered peroxide among marine natural products was reported in 1983 when Phillipson and Rinehart isolated plakinic acid A (18) from a sponge. Additional examples include plakinic acids C (19) and D (20) and epiplakinic acids C (21) and D (22), epiplakinic acid E methyl ester (23), (3R*,5S*,12E,-14E,17Z)-3,5-dimethyl-3,5-peroxydodeca-12,14,17-trienoic acid (24) and its methyl ester (25), and other related analogues. Many of the cyclic peroxides have been reported with submicromolar anticancer activity and were therefore further investigated as potential chemotherapeutic agents. In most
cases, however, the broad cytotoxicity profiles of these compounds rendered them unsuitable as anticancer drug candidates. Regardless, many of the cyclic peroxides are potently selective antiplasmodic agents that may be useful in fighting malaria. ¹⁵

Described below is the first example of cytotoxic β-carbolines coexisting with cytotoxic cyclic peroxides and related lipids in a marine sponge. The structures of eight new metabolites were elucidated by interpretation of spectroscopic data, and an analysis of the structural elucidation and bioactivity of these compounds is presented below.

**Isolation and structural elucidation**

The dark brown sponge *P. nigra* was collected by Pat Colin in Palau at a depth of 380 ft using a mixed gas rebreathing apparatus. The lyophilized sponge was extracted with methanol, and after removal of the solvent, the resulting material was partitioned between ethyl acetate and water. The aqueous extract was made basic with sodium hydroxide solution and again extracted with ethyl acetate (peroxy acids may have inadvertently been discarded or destroyed during this step). The ethyl acetate extracts, which exhibited activity against the HCT-116 human colon tumor cell line, were combined and fractionated on Sephadex LH-20 using methanol as an eluent to obtain plakortamines A (1, 144.4 mg, 0.61% dry wt), B (2, 15.0 mg, 0.063% dry wt), and C (3, 4.9 mg, 0.021% dry wt)
and several fractions that required further purification. One of these fractions was subjected to reversed-phase medium-pressure liquid chromatography on a Diaion HP-20SS column to obtain plakortamine D (4, 6.5 mg, 0.027% dry wt). Some of the fractions from the Sephadex column appeared by $^1$H NMR spectroscopy to consist of salts of the alkaloids and organic acids. After experiencing great difficulty in separating the acids from the plakortamines, and then suffering further losses while purifying the acids, I eventually succeeded in purifying epiplakinic acids G (5) and H (6) and two $\gamma$-lactones, 7 and 8. Owing to the difficulty that I experienced in separating the acids from the bases, the yields reported for compounds 1-8 do not reflect their true concentrations in the crude extract as judged by its $^1$H NMR spectrum, which indicated that the ratio of plakortamines to epiplakinic acids was about 1:1.

Plakortamine A (1) was isolated as an optically inactive pale yellow oil. The mass spectrum contained equal intensity peaks at 318/320, indicating the presence of bromine, and the high-resolution mass measurement ($m/z$ 318.0596, [M + H]$^+$) indicated a molecular formula of C$_{13}$H$_{16}$^79BrN$_3$, with 9 unsaturation equivalents. The UV spectrum contained absorptions at 243 nm and 295 nm (Figure 2.1), which, together with the presence of 11 signals in the aromatic region of the $^{13}$C NMR spectrum, suggested a heteroaromatic ring system. The $^1$H NMR data, with signals at $\delta12.52$ (br s, NH), 8.28 (d, 1 H, $J = 5.5$ Hz, H-3), 7.78 (d, 1 H, $J = 5.5$ Hz, H-4), 7.95 (d, 1 H, $J = 8.0$ Hz, H-5), 7.34 (dd, 1 H, $J = \ldots$)
Figure 2.1 UV spectrum for plakortamine A (1).

8.0, 1.5 Hz, H-6), and 7.67 (d, 1 H, J = 1.5 Hz, H-8), suggested that the heteroaaromatic ring system was a 1-substituted 7-bromo-β-carboline, which satisfies the requirement for 9 unsaturation equivalents. The $^{13}$C NMR spectrum, which was assigned using HSQC and HMBC data, confirmed the presence of a 1-substituted 7-bromo-β-carboline moiety. The remaining signals in the $^1$H NMR spectrum at δ2.47 (s, 6 H, NMe$_2$), 2.82 (t, 2 H, J = 5.5 Hz, H$_2$-11), and 3.36 (t, 2 H, J = 5.5 Hz, H$_2$-10) were assigned to a $N,N$-dimethylethylamine side chain, the position of which was determined by the HMBC correlations from the signals at
Figure 2.2 Enlargement of the HMBC spectrum for plakortamine A (1), which was used to assign the position of the $N,N$-dimethylethylamine side chain.

2.28 and 3.36 to a carbon signal at 144.0 (C-1) and from 3.36 to only one additional carbon signal at 135.9 (C-9a) (Figure 2.2). Thus plakortamine A (1) is 7-bromo-1-($N,N$-dimethylethylamino)-$\beta$-carboline.

Plakortamine B (2), the most bioactive of the alkaloids, was isolated as an optically inactive yellow oil. The mass spectrum contained $[M + H]^+$ peaks of equal intensity at 273/275, indicating the presence of bromine (Figure 2.3), and the high-resolution mass measurement indicated a molecular formula of $C_{13}H_9^{51}BrN_2$ ($m/z$ 275.0008, $[M + H]^+$). The $^{13}$C NMR spectra contained 13 signals in the aromatic/olefinic region, suggesting a heteroaromatic ring system (Figure 2.4). The $^1$H NMR spectrum contained signals assignable to a terminal
vinyl group at δ_H 5.72 (d, 1 H, J = 11 Hz), 6.40 (d, 1 H, J = 17 Hz), and 7.18 (dd, 1 H, J = 17, 11 Hz). In addition, signals at δ_H 8.61 (br s, 1 H, -NH), 8.48 (d, 1 H, J = 5.5 Hz, H-3), 7.97 (d, 1 H, J = 8 Hz, H-5), 7.84 (d, 1 H, J = 5.5 Hz, H-4), 7.69 (d, 1 H, J = 1.5 Hz, H-8), and 7.41 (dd, 1 H, J = 8, 1.5 Hz, H-6), suggested that the heteroaromatic ring system was a 1-substituted 7-bromo-β-carboline (Figure 2.5), which, along with the terminal olefin, satisfies the requirement for 10 unsaturation equivalents suggested by the molecular formula. An analysis of the HMBC spectrum confirmed the presence of a 1-substituted 7-bromo-β-carboline moiety. HMBC data was also used to assign the attachment site of the terminal olefin at C-1. Plakortamine B was therefore assigned the structure 7-bromo-1-vinyl-β-carboline (2).

Plakortamine C (3) was isolated as an optically inactive pale yellow gum. The molecular formula, C_{27}H_{32}N_{5}^{81}Br_{2} (m/z 578.0372, [M + H]^+), coupled with the presence of only 14 signals in the ^{13}C NMR spectrum, suggested that plakortamine C contained two 1-substituted 7-bromo-β-carboline groups. Assuming that each of the aromatic signals was due to 2 protons, the remaining signals in the ^{1}H NMR spectrum at δ_H 3.31 (t, 4 H, J = 5.5 Hz), 3.09 (t, 4 H, J = 5.5 Hz), and 2.58 (s, 3 H) were assigned to a -CH\_2-CH\_2-N(Me)-CH\_2-CH\_2- chain joining the two 7-bromo-β-carboline entities.

Plakortamine D (4), [α]_D -2.1° (c 0.6, MeOH), was obtained as a yellow oil. The molecular formula, C_{15}H_{14}^{79}BrN_{3}O (m/z 332.0385, [M + H]^+), required
10 unsaturation equivalents, nine of which were associated with a 7-bromo-β-carboline moiety. The $^1$H NMR spectrum contained an $N$-methyl signal at $\delta_H$ 2.99 (s, 3 H) and signals at 5.90 (dd, 1 H, $J = 8.5, 7$ Hz), 3.61 (t, 1 H, $J = 8$ Hz), 3.08 (m, 1 H), 2.80 (m, 1 H), and 2.53 (m, 1 H), which were shown by the COSY spectrum to be due to a O-CH-CH$_2$-CH$_2$-N unit. To account for the remaining unsaturation equivalent, there must be an N-O bond to form a ring, which is attached at C-1 to the carbon bearing oxygen (C-10). Further support for this structure came from the HMBC experiment that showed correlations from the $N$-methyl signal to C-12, from H-10 to C-1, C-9a, and C-11, and from H-11 (2.56) to C-1, C-10, and C-12. There was insufficient material to determine the absolute configuration at C-1.

![Compound Image]

**Figure 2.3** Positive (top) and negative (bottom) electrospray ionization mass spectra for plakortamine B (2).
Figure 2.5  Annotated $^1$H NMR spectrum for plakortamine B (2) in CDCl$_3$. 
A general mechanism for the formation of brominated β-carbolines such as 1-4 is illustrated in Figure 2.6. A nucleophilic addition of tryptamine to an aldehyde results in the formation of a Schiff base. Position 2 of the indole system is also nucleophilic due to the adjacent nitrogen and can now participate in an intramolecular Pictet-Spengler condensation, attacking the reactive iminium carbon to close the ring. The resulting tricyclic intermediate is then oxidized and brominated to give the β-carboline skeleton seen in the plakortamines.

**Figure 2.6** Biosynthetic mechanism for the formation of the β-carboline skeleton of the plakortamines.
Epiplakinic acid G (5), [α]_D -17.2° (c 0.3, MeOH), was isolated as a colorless gum. The molecular formula, C_{27}H_{44}O_4, was initially inferred from the high-resolution mass measurement of the [M + Na]^+ ion at m/z 455.3127. The ^{13}C NMR spectrum contained four signals at δ_C 143.8, 129.2 (2C), 129.0 (2C), and 126.4 that were assigned to a terminal phenyl group, a signal at 174.3 due to the carboxylic acid, two signals at δ_C 87.8 and 84.9 due to fully substituted carbon atoms bearing oxygen, and four methyl signals at δ_C 24.8, 24.1, 22.2, and 20.7 (Figure 2.7). The ^1H NMR spectrum confirmed the presence of the phenyl group and the four methyl groups that gave rise to signals at δ_H 1.46 (s, 3 H), 1.33 (s, 3 H), 0.95 (d, 3 H, J = 6.5 Hz), and 0.83 (d, 3 H, J = 7 Hz) (Figure 2.8). The signals at δ_H 1.46 and 1.33 were assigned to methyl groups on carbons bearing oxygen. Interpretation of the HSQC and HMBC spectra suggested the presence of a five-membered cyclic peroxide moiety. The C-2 methylene signals at δ_H 2.77 (d, 1 H, J = 16 Hz) and 2.73 (d, 1 H, J = 16 Hz) showed HMBC correlations to the carboxylic acid signal at δ_C 174.3 (C-1) and to signals at 84.9 (C-3), 58.3 (C-4), and 24.8 (C-24, δ_H 1.46). The Me-24 signal at δ_H 1.46 showed HMBC correlations to C-2, C-3, and C-4, while the Me-25 signal at 1.33 showed correlations to C-4, C-5 (87.8), and C-6 (47.5). Since C-3 and C-5 are the only carbon atoms bearing oxygen, there must be a peroxide bridge linking the two carbons in order to satisfy both the number of oxygens and the number of unsaturation equivalents in the molecule. The Me-26 signal at δ_H 0.95 (d, 3 H, J
Figure 2.7 $^{13}$C NMR spectrum for epiplakinic acid G (5) in MeOH-$d_4$. 
Figure 2.8 $^1$H NMR spectrum for epiplakinic acid G (5) in CDCl$_3$. Inset shows downfield portion of the spectrum.
= 6.5 Hz) showed HMBC correlations to signals at 47.5 (C-6), 28.1 (C-7), and 47.9 (C-8), while the Me-27 signal at 0.83 (d, 3 H, J = 7 Hz) was correlated to signals at 47.9 (C-8), 30.7 (C-9), and 37.9 (C-10). These correlations established the structure of the C-1 to C-10 portion of the molecule. The H_2-17 signal at δ_H 2.59 (t, 2 H, J = 8 Hz) showed HMBC correlations to signals at 143.8 (C-18), 129.0 (C-19, 23), and 32.7 (C-15). The remaining methylene signals must be due to a linear chain between C-10 and C-15.

The relative stereochemistry about the peroxide ring was established by the observation of NOEs between Me-24 and the H-4β signal at δ_H 2.22 (d, 1 H, J = 13 Hz) and between Me-25 and the H-4α signal at 2.49 (d, 1 H, J = 13 Hz) (Figure 2.9). Unfortunately no useful NOEs were observed that could be used to assign the relative stereochemistry at C-26 or C-27.

Epiplakinic acid H (6), [α]_D +33° (c 0.07, MeOH), was isolated as a colorless gum. The molecular formula, C_{27}H_{44}O_{4}, which is the same as that of epiplakinic acid G (5), was defined from the high-resolution mass measurement of the [M + Na]⁺ ion at m/z 455.3128. The ¹H and ¹³C NMR spectra were so similar to those of 5 that it was apparent that epiplakinic acid H (6) was an epimer of epiplakinic acid G (5) at either C-3 or C-5. This was confirmed by the observation of NOE correlations from both the Me-24 signal at δ_H 1.48 and the Me-25 signal at 1.37 to the H-4β signal at 2.22 in the ROESY spectrum. The H-4α signal at δ_H 2.47 showed correlations to the C-2 signal at 2.73 and a signal at
Figure 2.9 1D-NOESY correlations (dashed arcs) for cyclic peroxide portion of epiplakinic acid G (5).
1.64 that was assigned to H-7. Since the $^{13}$C NMR signals of Me-26 and Me-27 are nearly identical in both compounds, I consider it preferable to assign the same stereochemistry at C-5, C-7, and C-9, implying that 5 and 6 are epimeric at C-3.

Both (2S*,4R*)- and (2R*,4R*)-2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactones (7 and 8) were isolated as colorless oils. They had the same molecular formula, C$_{24}$H$_{38}$O$_2$, which was determined by high-resolution mass measurement of the [M + Na]$^+$ ions at $m/z$ 381.2763 and 381.2770, respectively. The IR bands at 1765 cm$^{-1}$ indicated that both compounds contained a $\gamma$-lactone ring, which, together with a phenyl ring, accounted for the six degrees of unsaturation required by the molecular formula. The $^1$H and $^{13}$C NMR spectra of 7 and 8 were remarkably similar, especially the signals due to the monosubstituted phenyl ring and the attached linear alkyl chain, with the only notable differences being associated with the substituents about the $\gamma$-lactone ring (Figure 2.10). In the case of lactone 7, the COSY spectrum revealed coupling from the methyl doublet at $\delta_H$ 1.21 ($J = 7$ Hz, Me-23) to the H-2 methine signal at 2.91, which must be adjacent to the lactone carbonyl and which was in turn coupled to the H-3 signals at 2.27 and 1.72. The methyl singlet at $\delta_H$ 1.34 must be adjacent to the only remaining fully substituted carbon at 86.1, which must also be attached to the lactone oxygen, the alkyl chain, and the methylene group at C-3. The HMBC data confirmed the presence of the $\gamma$-lactone ring and its substituents. The Me-23 signal showed correlations to C-1 ($\delta_C$ 181.6),
Figure 2.10 Comparison of the upfield region of the $^1$H NMR spectra for 7 (top) and 8 (bottom). Arrows indicate the chemical shift of H-3$\alpha$, which changes due to the relative stereochemistry of C-2 and C-4. Truncated portion of the molecules shown for clarity.
C-2 (36.3), and C-3 (42.5), while the Me-24 signal showed correlations to C-3, C-4 (86.1), and C-5 (42.8). The ROESY spectrum showed weak correlations between the Me-23 signal and the H-3α signal at δH 1.72 and between the Me-24 signal and the H-3β signal at 2.27, while the H-2 signal showed a stronger correlation to the H-3β signal than to the H-3α signal, all of which supported the 2S*,4R* stereochemistry. A similar analysis of the NMR data for lactone 8 revealed that its planar structure was the same as that of lactone 7. The ROESY spectrum of 8 did not show strong correlations from the Me-23 and Me-24 signals to either of the H-3 signals, but since there are only two chiral centers in the compound, lactone 8 must have the 2R*,4R* stereochemistry.

All of the metabolites tested exhibited activity against the HCT-116 human colon tumor cell line. The most active alkaloid was plakortamine B (2, IC₅₀ 0.62 μM), followed by plakortamine A (1, IC₅₀ 3.2 μM) and plakortamine D (4, IC₅₀ 15 μM) (Figure 2.11). Epiplakinic acids G (5, IC₅₀ 0.16 μM) and H (6, IC₅₀ 0.39 μM) were also moderately active, and even lactone 7 (IC₅₀ 14.5 μM), but not lactone 8, showed mild activity.

The text of this chapter is, in part, a reprint of the material as it appears in the Journal of Natural Products 2002, 65, 1258-61 with co-authors Patrick L. Colin, John N.A. Hooper, and D. John Faulkner. I was the primary researcher and author, and the co-authors listed in this publication helped direct and supervise the research, which forms the basis of this chapter.
Figure 2.11 Dose-response curve of human cancer cells (HCT-116) exposed to compounds 1, 2, and 4.
Experimental

General Methods. Optical rotations were measured on a Rudolf Autopol III polarimeter (c g/100 mL) at 589 nm. IR spectra were recorded on a Perkin-Elmer 1600 FT-IR spectrophotometer. UV spectra were obtained using a Perkin-Elmer Lambda Bio-20 spectrophotometer. $^1$H, COSY, HMBC, HMQC, and ROESY NMR spectra were measured on a Varian Inova 300 MHz spectrometer. $^{13}$C and DEPT spectra were measured on a Varian Gemini 400 MHz spectrometer. ESIMS spectra were recorded using a Finnigan LCQ mass spectrometer. High-resolution FABMS data were obtained on a VG ZAB mass spectrometer at the U. C. Riverside Regional Facility. All solvents were distilled prior to use.

Extraction and Purification. The dark brown sponge, identified by Dr. John Hooper as Plakortis nigra Levi, 1959 (Plakinidae, Homosclerophida), was hand-collected by Pat Colin from a depth of 380 ft at Palau using a mixed gas rebreathing apparatus. A voucher specimen has been deposited in the SIO Benthic Invertebrate Collection (# P1181). The diced, lyophilized sponge (61.4 g dry wt) was repeatedly extracted with MeOH at room temperature to obtain a dark brown oil (8.1 g). After the extract had been partitioned between EtOAc and H$_2$O, the aqueous extract was basified with dilute sodium hydroxide to pH 10 and again extracted with EtOAc. The combined EtOAc extracts (1.3 g), which exhibited activity against the HCT-116 cell line, were chromatographed on Sephadex LH-20 using MeOH as eluant to obtain plakortamines A (1, 144 mg, 0.61% yield), B (2, 15 mg, 0.063% yield), and C (3, 4.9 mg, 0.021% yield). One
of the fractions from LH-20 was further purified by medium-pressure chromatography on Diaion HP-20SS using gradient elution from 20% MeOH in H₂O to MeOH to obtain plakortamine D (4, 6.5 mg, 0.027% yield). Our first attempts to separate the most cytotoxic LH-20 fractions were unsuccessful and resulted in loss of the material, which consisted mainly of epiplakinic acids. However, several cytotoxic LH-20 fractions were combined and chromatographed on silica gel using a stepwise gradient from 20% EtOAc in hexanes to 100% EtOAc to obtain several active fractions that contained phenyl signals in their \(^1\)H NMR spectra. The most active of these fractions were combined and chromatographed by HPLC on silica using 20% EtOAc in hexanes to obtain epiplakininc acid G (5, 4.7 mg) and epiplakinic acid H (6, 1 mg). The less polar fractions were combined and chromatographed by HPLC on silica using 10% EtOAc in hexanes to obtain \((2S*,4R*)\)-2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone (7, 1.9 mg) and \((2R*,4R*)\)-2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone (8, 0.7 mg).

**HCT-116 Assay.** The HCT-116 cells were plated by Catherine Sincich in 96-well plates and incubated overnight at 37°C in 5% CO₂/air. Compounds were added to the plate and serially diluted. The plate was then incubated for a further 72 h. Cell viability was assessed at the end of this period through the use of a CellTiter 96 AQquous non-radioactive cell proliferation assay (Promega). Inhibition concentration (IC\(_{50}\)) values are interpreted from the bioreduction of MTS/PMS by
living cells into a formazan product. The first step of the assay is the addition of MTS/PMS to the sample wells followed by a 3 h incubation. The quantity of the formazan product (proportional to the number of living cells) in each well was then determined using a Molecular Devices Emax microplate reader that measured the amount of 490 nm absorbance in each well, and the IC_{50} value was calculated by a SOFTMax analysis program. Etoposide (Sigma) and DMSO (solvent) were used as positive and negative controls, respectively.

**Plakortamine A (1):** pale yellow oil; UV (MeOH) 243 nm (ε 20 000), 295 nm (ε 11 700); IR (film) 3200 (br), 1620, 1570 cm^{-1}; ^1H NMR (CDCl₃, 300 MHz) δ_H 12.52 (br s, 1 H, -NH), 8.28 (d, 1 H, J = 5.5 Hz, H-3), 7.95 (d, 1 H, J = 8 Hz, H-5), 7.78 (d, 1 H, J = 5.5 Hz, H-4), 7.67 (d, 1 H, J = 1.5 Hz, H-8), 7.34 (dd, 1 H, J = 8, 1.5 Hz, H-6), 3.36 (t, 2 H, J = 5.5 Hz, H-10), 2.82 (t, 2 H, J = 5.5 Hz, H-11), 2.47 (s, 6 H, NMe₂); ^13C NMR (MeOH-d₄, 400 MHz) δ_C 144.0 (C-1), 143.1 (C-8a), 138.7 (C-3), 135.9 (C-9a), 129.8 (C-4a), 124.0 (C-5), 124.0 (C-6), 123.0 (C-7), 121.5 (C-4b), 115.7 (C-8), 114.5 (C-4), 58.5 (C-11), 44.7 (NMe₂), 30.9 (C-10); HREIMS [M + H]^+ m/z 318.0596 (calcd for C_{15}H_{17}BrN₃, 318.0606).

**Plakortamine B (2):** yellow oil; UV (MeOH) 214 nm (ε 32 000); IR (film) 3200 (br), 1620, 1560, 1235 cm^{-1}; ^1H NMR (CDCl₃, 300 MHz) δ_H 8.61 (br s, 1 H, -NH), 8.48 (d, 1 H, J = 5.5 Hz, H-3), 7.97 (d, 1 H, J = 8 Hz, H-5), 7.84 (d, 1 H, J = 5.5 Hz, H-4), 7.69 (d, 1 H, J = 1.5 Hz, H-8), 7.41 (dd, 1 H, J = 8, 1.5 Hz, H-6), 7.18 (dd, 1 H, J = 17, 11 Hz, H-10), 6.40 (d, 1 H, J = 17 Hz, H-11), 5.72 (d, 1 H, J =
$^{13}$C NMR (MeOH-$d_4$, 400 MHz) δ141.9 (C-8a), 139.8 (C-1), 137.8 (C-3), 133.9 (C-9a), 131.6 (C-10), 129.4 (C-4a), 122.8 (C-5), 122.6 (C-6), 121.7 (C-7), 119.9 (C-4b), 118.5 (C-11), 114.3 (C-8), 113.8 (C-4); HREIMS [M + H]$^+$ m/z 275.0008 (calcd for C$_{13}$H$_{10}^{81}$BrN$_2$, 275.0007).

Plakortamine C (3): pale yellow oil; UV (MeOH) 243 nm (ε 57 400), 296 nm (ε 29 000); IR (film) 3200 (br), 1620, 1570 cm$^{-1}$; $^1$H NMR (MeOH-$d_4$, 300 MHz) δH 8.14 (d, 2 H, J = 5.5 Hz, H-3), 7.96 (d, 2 H, J = 8 Hz, H-5), 7.77 (d, 2 H, J = 5.5 Hz, H-4), 7.53 (d, 2 H, J = 1.5 Hz, H-8), 7.32 (dd, 2 H, J = 8, 1.5 Hz, H-6), 3.31 (t, 4 H, J = 5.5 Hz, H-10), 3.09 (t, 4 H, J = 5.5 Hz, H-11), 2.58 (s, 3 H, NMe$_2$); $^{13}$C NMR (MeOH-$d_4$, 400 MHz) δC 143.9 (C-1,1'), 142.9 (C-8a,8a'), 138.5 (C-3,3'), 135.8 (C-9a,9a'), 129.6 (C-4a,4a'), 124.0 (C-5,5'), 123.9 (C-6,6'), 122.9 (C-7,7'), 121.4 (C-4b,4b'), 115.7 (C-8,8'), 114.3 (C-4,4'), 56.3 (C-11,11'), 41.7 (NMe), 30.4 (C-10,10'); HREIMS [M + H]$^+$ m/z 578.0372 (calcd for C$_{27}$H$_{24}^{79}$Br$^{81}$BrN$_5$, 578.0379).

Plakortamine D (4): pale yellow oil; [α]$_D$ -2.1° (c 0.6, MeOH); UV (MeOH) 243 nm (ε 26 600), 296 nm (ε 14 700); IR (film) 3400 (br), 1625, 1570, 1420 cm$^{-1}$; $^1$H NMR (CDCl$_3$, 300 MHz) δH 11.37 (br s, 1 H, -NH), 8.29 (d, 1 H, J = 5.5 Hz, H-3), 7.99 (d, 1 H, J = 8 Hz, H-5), 7.95 (d, 1 H, J = 5.5 Hz, H-4), 7.78 (d, 1 H, J = 1.5 Hz, H-8), 7.41 (dd, 1 H, J = 8, 1.5 Hz, H-6), 5.90 (dd, 1 H, J = 8.5, 7 Hz, H-10) 3.61 (t, 1 H, J = 8 Hz, H-12), 3.08 (m, 1 H, H-11), 2.99 (s, 3 H, NMe), 2.80 (m, 1 H, H-12), 2.53 (m, 1 H, C-11); $^{13}$C NMR (CDCl$_3$, 400 MHz) δC 145.3 (C-...
1), 141.8 (C-8a), 134.5 (C-3), 132.0 (C-9a), 130.4 (C-4a), 123.6 (C-5), 123.1 (C-7), 122.9 (C-6), 119.9 (C-4b), 115.2 (C-8), 114.5 (C-4), 79.1 (C-10), 58.2 (C-12), 45.0 (NMe), 37.0 (C-11); HREIMS [M + H]^+ m/z 332.0385 (calcd for C_{15}H_{15}^{79}BrN_{3}O, 332.0399).

**Epiplakinic acid G (5):** colorless oil; [α]_D -17.2° (c 0.3, MeOH); UV (MeOH) 255 nm (ε 253), 260 nm (ε 276), 269 nm (ε 218); IR (film) 3300 (br), 1705, 1450 cm⁻¹; ^1^H NMR (CDCl₃, 300 MHz) δ_H 7.24 (t, 2 H, J = 7.5 Hz), 7.18 (m, 3 H), 2.77 (d, 1 H, J = 16 Hz, H-2), 2.73 (d, 1 H, J = 16 Hz, H-2), 2.59 (t, 2 H, J = 8 Hz, H₂-17), 2.49 (d, 1 H, J = 13 Hz, H-4), 2.22 (d, 1 H, J = 13 Hz, H-4), 1.46 (s, 3 H, Me-24), 1.33 (s, 3 H, Me-25), 0.95 (d, 3 H, J = 6.5 Hz, Me-26), 0.83 (d, 3 H, J = 7 Hz, Me-27); ^1^C NMR (MeOH-d₄, 400 MHz) δ_C 174.3 (C-1), 143.8 (C-18), 129.2 (C-20,22), 129.0 (C-19,23), 126.4 (C-21), 87.8 (C-5), 84.9 (C-3), 58.3 (C-4), 47.9 (C-8), 47.5 (C-6), 45.3 (C-2), 37.9 (C-10), 36.9 (C-17), 32.7 (C-15), 31.1, 31.0, 30.7 (C-9), 30.6, 30.3, 28.1 (C-7), 27.9 (C-16), 24.8 (C-24), 24.1 (C-25), 22.2 (C-26), 20.7 (C-27); ESIMS (+ve) m/z 455 [M + Na]^+, (-ve) 431 [M - H]; HRMALDIMS [M + Na]^+ m/z 455.3127 (calcd for C_{27}H_{44}O_{4}Na, 455.3132).

**Epiplakinic acid H (6):** colorless oil; [α]_D +33° (c 0.07, MeOH); UV (MeOH) 254 nm (ε 269), 259 nm (ε 270), 268 nm (ε 212); IR (film) 3300 (br), 1705, 1455 cm⁻¹; ^1^H NMR (MeOH-d₄, 300 MHz) δ_H 7.22 (t, 2 H, J = 7.5 Hz), 7.16 (m, 3 H), 2.76 (d, 1 H, J = 16 Hz, H-2), 2.73 (d, 1 H, J = 16 Hz, H-2), 2.59 (t, 2 H, J = 8 Hz, H₂-17), 2.47 (d, 1 H, J = 13 Hz, H-4), 2.22 (d, 1 H, J = 13 Hz, H-4), 1.48 (s, 3 H,
Me-24), 1.37 (s, 3 H, Me-25), 0.91 (d, 3 H, J = 6.5 Hz, Me-26), 0.83 (d, 3 H, J = 7 Hz, Me-27); \(^{13}\)C NMR (MeOH-\(d_4\), 400 MHz) \(\delta_C\) 175.2 (C-1), 143.8 (C-18), 129.2 (C-20,22), 129.0 (C-19,23), 126.4 (C-21), 87.9 (C-5), 84.9 (C-3), 58.3 (C-4), 47.7 (C-8), 47.2 (C-6), 46.4 (C-2), 37.8 (C-10), 36.9 (C-17), 32.8 (C-15), 31.2, 31.0, 30.7 (C-9), 30.6, 30.3, 28.2 (C-7), 27.9 (C-16), 24.8 (C-24), 24.4 (C-25), 22.1 (C-26), 20.7 (C-27); HRMALDIMS [M + Na]^+ \(m/z\) 455.3128 (calcd for C\(_{27}\)H\(_{44}\)O\(_4\)Na, 455.3132).

\((2S^*,4R^*)\)-2,4-Dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone (7): colorless oil; \([\alpha]_D\) -7.1° (c 0.13, MeOH); UV (MeOH) 254 nm (\(\varepsilon\) 196), 261 nm (c 215) 268 nm (\(\varepsilon\) 170); IR (film) 1765, 1450 cm\(^{-1}\); \(^1\)H NMR (MeOH-\(d_4\), 300 MHz) \(\delta_H\): 7.22 (t, 2 H, J = 7.5 Hz), 7.16 (m, 3 H), 2.91 (m, 1 H), 2.58 (t, 2 H, J = 8 Hz), 2.27 (dd, 1 H, J = 12.5, 9 Hz), 1.72 (dd, 1 H, J = 12.5, 11.5 Hz), 1.67 (m, 2 H), 1.59 (m, 2 H), 1.34 (s, 3 H), 1.31-1.28 (m, 18 H), 1.21 (d, 3 H, J = 7 Hz); \(^{13}\)C NMR (MeOH-\(d_4\), 400 MHz) \(\delta_C\): 181.6 (C-1), 143.8 (C-17), 129.2 (C-19,21), 129.0 (C-18,22), 126.4 (C-20), 86.1 (C-4), 42.8 (C-5), 42.5 (C-3), 36.9 (C-16), 36.3 (C-2), 32.8 (C-14), 31.0, 30.6-30.7 (6C), 30.3 (C-15), 24.9 (C-24), 24.9 (C-6), 15.7 (C-23); HRMALDIMS [M + Na]^+ \(m/z\) 381.2763 (calcd for C\(_{24}\)H\(_{36}\)O\(_3\)Na, 381.2764).

\((2R^*,4R^*)\)-2,4-Dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone (8): colorless oil: \([\alpha]_D\) +19.3° (c 0.05, MeOH); UV (MeOH) 252 nm (\(\varepsilon\) 326), 258 nm (c 296) 268 nm (\(\varepsilon\) 235); IR (film) 1765, 1455 cm\(^{-1}\); \(^1\)H NMR (MeOH-\(d_4\), 300
MHz) δH 7.22 (t, 2 H, J = 7.5 Hz), 7.16 (m, 3 H), 2.86 (m, 1 H), 2.58 (t, 2 H, J = 8 Hz), 2.43 (dd, 1 H, J = 12.5, 9 Hz), 1.66 (dd, 1 H, J = 12.5, 11.5 Hz), 1.59 (m, 4 H), 1.39 (s, 3 H), 1.31-1.28 (m, 18 H), 1.22 (d, 3 H, J = 7 Hz); 13C NMR (MeOH-d4, 400 MHz) δC 181.6 (C-1), 143.8 (C-17), 129.2 (C-19,21), 129.0 (C-18,22), 126.4 (C-20), 86.3 (C-4), 42.6 (C-3), 41.1 (C-5), 36.9 (C-16), 36.8 (C-2), 32.8 (C-14), 31.0, 30.6-30.7 (6C), 30.3 (C-15), 27.2 (C-24), 25.3 (C-6), 16.3 (C-23); HRMALDIMS [M + Na]+ m/z 381.2770 (calcd for C24H38O2Na, 381.2764).
References


CHAPTER 3

ERYLOSIDES A, K, AND L: BIOACTIVE STEROIDAL GLYCOSIDES FROM THE MARINE SPONGE ERYLUS LENDENFELDI

An assay was used to identify three compounds, erylosides A, K, and L (1-3), that were selectively toxic to a Δrad50 yeast strain deficient in DNA double-strand break repair. The structures were established based mainly on 1D and 2D NMR data, and the absolute stereochemistry of erylosides A and K were determined by chemical means. The biological activity of these compounds was further investigated.

This work originally appeared in Tetrahedron 2005, 61, 1199-1206 with co-authors Susan L. Forsburg and D. John Faulkner. It has been rewritten here for continuity and so that my contribution be clarified.

Introduction

The modern approach to finding new anticancer drugs relies on the discovery of compounds that target the subtle molecular differences between malignant and healthy human cells.¹ In recent years, the integration of genetics and drug discovery has resulted in the engineering of a wide array of molecular

---

alterations in model organisms that can be used to screen for selectively bioactive small molecules. In particular, budding yeast (*Saccharomyces cerevisiae*) have proven to be an excellent model for discovering novel anticancer drugs.² Budding yeast is a simple, single-celled eukaryotic organism with a completely sequenced and comprehensively characterized genome. The advantages of using yeast as a model system include the high degree of conservation of DNA-repair pathways with higher eukaryotes, the ease of handling relative to human cell lines, and the availability of advanced molecular genetic techniques for subsequent analysis. The use of matched pairs of yeast strains (i.e. one strain with a defined genetic alteration and the other with the corresponding wild-type gene) has facilitated the identification of selectively toxic compounds whose mechanisms of action can take advantage of any differences between the strains.³ A cell line containing a mutation in a gene whose human homolog is implicated in cancer (e.g. DNA-damage repair, cell-division checkpoint) can therefore be used as a model of a human cancer cell. However, unlike cancer cell lines that contain numerous genetic instabilities and complexities, yeast strains can be designed with single mutations, providing a simpler model for the identification of compounds that target specific biochemical pathways.

In 2000, Simon *et al.* developed a panel of isogenic yeast strains, each defective in a different DNA repair or cell cycle checkpoint function, and tested the panel for sensitivity to FDA-approved anticancer agents.⁴ A wide range of
toxicity profiles were observed for the drugs, reflecting differences in their mechanisms of action. For example, alkylating agents such as cisplatin (4) and nitrogen mustard (5) were specifically toxic to strains defective for the Rad6/Rad18-controlled pathway of DNA damage tolerance during S-phase, exhibiting 10-fold higher toxicity in Δrad6 and Δrad18 strains than other sensitive strains. Cell lines deficient in nucleotide excision repair (Δrad1 and Δrad14), recombinational repair (Δrad50, Δrad51, and Δrad52), and error-prone damage tolerance (Δrev1, Δrev3, and Δrad6) were also somewhat sensitive, reflecting the roles of such pathways in the repair of DNA cross-links caused by these alkylating agents. Cytarabine monophosphate (6), which is known to inhibit DNA synthesis, exhibited selective toxicity against a Δsgs1 strain. The Δsgs1 yeast mutant and the homologous Bloom’s and Werner’s syndrome defects in humans cause hyperrecombination, and sensitivity of the Δsgs1 strain to 6 suggested an effect on recombination that required the Sgs1 protein for tolerance.

Several topoisomerase poisons exhibited selectivity for the double-strand break (DSB) repair-deficient mutants Δrad50, Δrad51, and Δrad52. Topoisomerase poisons stabilize the covalent complex of topoisomerase and DNA ends during DNA relaxation and lead to single-strand breaks and DSBs for topo I and topo II poisons, respectively. The single-strand breaks caused by topo I poisons are converted to DSBs during DNA replication. Rad50, Rad51, and Rad52 are needed for repair of double-strand DNA breaks, and defects in both
human Rad50 and human topoisomerase enzymes have been associated with many types of cancer.\textsuperscript{10-13} The topo I poison camptothecin (7), along with the topo II poisons mitoxantrone (8) and idarubicin (9), were selectively toxic to DSB repair mutants, providing a direct link between DSB repair defects and vulnerability to topoisomerase inhibition in yeast.

In addition to providing robust information regarding the mechanism of action for known anticancer agents, a panel of budding yeast mutants can be used to discover novel bioactive compounds. Dunstan \textit{et al.} modified the aforementioned assay to identify new compounds that were selectively toxic to DSB repair mutants.\textsuperscript{3} After screening 85,000 pure compounds, 126 were identified to be selectively toxic to DSB repair mutants, 39 of which were structurally unrelated to known topoisomerase poisons. Compounds identified in the screen were further analyzed by use of yeast and vertebrate cell-based and \textit{in vitro} assays to distinguish between topo I and II poisons. Among these compounds, two novel topo II poisons were identified that were equipotent with the drug etoposide (10), and one compound was shown to directly bind DNA and induce strand breaks. The use of yeast strains with defined genetic alterations was thereby validated as a powerful tool for the discovery of novel, bioactive compounds that selectively target a biomedically relevant pathway.

In an attempt to identify compounds from marine organisms that targeted cancer-related pathways in yeast, I initiated a collaboration with Susan Forsburg’s
laboratory at the Salk Institute for Biological Studies. Dr. Forsburg’s research is focused primarily on yeast cell biology and cell-cycle genetics, and her group provided an ideal environment in which to adapt and implement the yeast assay developed by Simon et al.\textsuperscript{4} Our goal was to find new marine natural products that selectively targeted yeast strains deficient in DNA damage detection or damage repair pathways. Crude extracts from the Faulkner library of marine invertebrates were screened, and several extracts exhibited selective activity profiles against a panel of yeast mutants. The methanol extract from the Red Sea sponge \textit{Erylus lendenfeldi} Sollas,\textsuperscript{14} 1888 (Demospongiae, Astrophorida, Geodiidae) targeted a $Arad50$ strain deficient in DSB repair. The known compound, eryloside A (1), along with two new compounds, erylosides K (2) and L (3), were subsequently purified from the extract and their structures were determined by spectroscopic and chemical means.

The erylosides belong to a class of compounds collectively known as steroidal glycosides. Steroidal and triterpenoid oligoglycosides are the predominant metabolites of starfishes and sea-cucumbers, respectively.\textsuperscript{15} More recently, glycosides have been isolated from some sponges. The erylosides are a series of unusual and bioactive steroidal glycosides isolated from sponges of the genus \textit{Erylus}. Eryloside A (1), a 4-methyl steroidal diglycoside, was originally reported to possess anticancer and antifungal activity.\textsuperscript{16} Surprisingly, this original
report also mentions the presence of an additional analog, eryloside B, but provides no structural information pertaining to this molecule. Erylosides C (11) and D (12), which are composed of three and four D-galactopyranose units respectively, were reported with no biological activity. Eryloside E (13), however, displayed immunosuppressive activity without the presence of toxic side-effects. Compounds 11-13 each possessed a rare penasterol nucleus with a \( t \)-butyl substituent on its side-chain. Eryloside F (14) was shown to possess potent thrombin receptor antagonist activity, and erylosides G-J (15-18) all exhibited moderate cytotoxicity against a human leukemia cell line. An analysis of the structural elucidation and bioactivity of erylosides A, K, and L is presented below.

**Isolation and structural elucidation**

The marine sponge *Erylus lendenfeldi* was collected in February, 2000 in the Red Sea just north of Hurghada. Bioassay-guided fractionation led to the isolation of the known steroidal glycoside, eryloside A (1, 720 mg, 0.4% dry weight), along with two new steroidal glycosides, eryloside K (2, 145 mg, 0.08% dry weight), and eryloside L (3, 90 mg, 0.05% dry weight). The molecular formula of eryloside A (1) was determined to be \( \text{C}_{40}\text{H}_{66}\text{O}_{12} \) by high resolution MALDI-MS \((m/z 761.4472 ([M+Na]^+)\). The spectral properties of 1 (Table 3.1) were identical with the reported values for eryloside A, a \( 3\beta-O-\{\beta-D-\)
14

15 \( R = \text{CH}_2\text{OH} \)

16 \( R = \text{H} \)

17 \( R = \text{CH}_2\text{OH} \)

18 \( R = \text{H} \)
Table 3.1 $^{13}$C (100 MHz, MeOH-$d_4$) and $^1$H (300 MHz, MeOH-$d_4$) NMR data for compounds 1 and 3.

<table>
<thead>
<tr>
<th>C#</th>
<th>$^{13}$C NMR in ppm</th>
<th>$^1$H NMR in ppm, mult. ($J$ in Hz)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>36.6</td>
<td>36.2</td>
</tr>
<tr>
<td></td>
<td>1.24 m</td>
<td>1.25 m</td>
</tr>
<tr>
<td></td>
<td>1.87 m</td>
<td>1.89 m</td>
</tr>
<tr>
<td></td>
<td>1.61 m</td>
<td>1.62 m</td>
</tr>
<tr>
<td></td>
<td>2.13 m</td>
<td>2.13 m</td>
</tr>
<tr>
<td>2</td>
<td>31.0</td>
<td>30.5</td>
</tr>
<tr>
<td></td>
<td>3.16 dt (10.6, 5.2)</td>
<td>3.17 dt (10.6, 5.1)</td>
</tr>
<tr>
<td>3</td>
<td>87.9</td>
<td>87.4</td>
</tr>
<tr>
<td></td>
<td>1.51 dd (11.4, 10.6)</td>
<td>1.51 dd (11.0, 10.8)</td>
</tr>
<tr>
<td>4</td>
<td>39.1</td>
<td>38.7</td>
</tr>
<tr>
<td></td>
<td>1.07 ddd (12.2, 11.4, 2.4)</td>
<td>1.08 ddd (12.0, 10.8, 2.4)</td>
</tr>
<tr>
<td>5</td>
<td>49.1</td>
<td>48.7</td>
</tr>
<tr>
<td></td>
<td>1.30 m</td>
<td>1.31 m</td>
</tr>
<tr>
<td></td>
<td>1.85 m</td>
<td>1.88 m</td>
</tr>
<tr>
<td></td>
<td>2.13 m</td>
<td>2.13 m</td>
</tr>
<tr>
<td></td>
<td>2.25 m</td>
<td>2.25 m</td>
</tr>
<tr>
<td>6</td>
<td>21.9</td>
<td>21.5</td>
</tr>
<tr>
<td></td>
<td>2.21 m</td>
<td>2.23 m</td>
</tr>
<tr>
<td></td>
<td>1.37 m</td>
<td>1.38 m</td>
</tr>
<tr>
<td></td>
<td>2.05 m</td>
<td>2.02 m</td>
</tr>
<tr>
<td>7</td>
<td>28.1</td>
<td>27.6</td>
</tr>
<tr>
<td></td>
<td>2.13 m</td>
<td>2.13 m</td>
</tr>
<tr>
<td></td>
<td>2.25 m</td>
<td>2.25 m</td>
</tr>
<tr>
<td>8</td>
<td>124.1</td>
<td>123.6</td>
</tr>
<tr>
<td>9</td>
<td>141.6</td>
<td>141.5</td>
</tr>
<tr>
<td>10</td>
<td>38.0</td>
<td>37.6</td>
</tr>
<tr>
<td>11</td>
<td>22.9</td>
<td>22.5</td>
</tr>
<tr>
<td></td>
<td>5.34 s</td>
<td>5.34 s</td>
</tr>
<tr>
<td>12</td>
<td>38.5</td>
<td>38.0</td>
</tr>
<tr>
<td></td>
<td>2.07 m</td>
<td>2.07 m</td>
</tr>
<tr>
<td></td>
<td>2.34 m</td>
<td>2.30 m</td>
</tr>
<tr>
<td>13</td>
<td>46.3</td>
<td>46.2</td>
</tr>
<tr>
<td>14</td>
<td>152.1</td>
<td>152.2</td>
</tr>
<tr>
<td>15</td>
<td>118.2</td>
<td>117.4</td>
</tr>
<tr>
<td>16</td>
<td>37.1</td>
<td>36.7</td>
</tr>
<tr>
<td></td>
<td>1.48 m</td>
<td>1.55 m</td>
</tr>
<tr>
<td></td>
<td>0.84 s</td>
<td>0.86 s</td>
</tr>
<tr>
<td>17</td>
<td>59.4</td>
<td>58.1</td>
</tr>
<tr>
<td>18</td>
<td>16.3</td>
<td>15.8</td>
</tr>
<tr>
<td></td>
<td>1.02 s</td>
<td>1.04 s</td>
</tr>
<tr>
<td>19</td>
<td>19.9</td>
<td>19.4</td>
</tr>
<tr>
<td>20</td>
<td>31.9</td>
<td>31.7</td>
</tr>
<tr>
<td></td>
<td>0.97 d (6.6)</td>
<td>0.94 d (5.6)</td>
</tr>
<tr>
<td>21</td>
<td>45.6</td>
<td>50.9</td>
</tr>
<tr>
<td></td>
<td>1.01 m</td>
<td>2.21 m</td>
</tr>
<tr>
<td></td>
<td>1.47 m</td>
<td>2.49 m</td>
</tr>
<tr>
<td>22</td>
<td>67.5</td>
<td>213.3</td>
</tr>
<tr>
<td></td>
<td>1.15 m</td>
<td>2.32 m</td>
</tr>
<tr>
<td></td>
<td>1.37 m</td>
<td>2.29 m</td>
</tr>
<tr>
<td>23</td>
<td>49.3</td>
<td>53.0</td>
</tr>
<tr>
<td>24</td>
<td>25.9</td>
<td>25.3</td>
</tr>
<tr>
<td></td>
<td>1.75 m</td>
<td>2.08 m</td>
</tr>
<tr>
<td>25</td>
<td>23.9</td>
<td>22.5</td>
</tr>
<tr>
<td></td>
<td>0.90 d (6.4)</td>
<td>0.90 d (6.4)</td>
</tr>
<tr>
<td>26</td>
<td>22.7</td>
<td>22.6</td>
</tr>
<tr>
<td></td>
<td>0.92 d (6.2)</td>
<td>0.91 d (6.4)</td>
</tr>
<tr>
<td>27</td>
<td>16.0</td>
<td>15.6</td>
</tr>
<tr>
<td></td>
<td>1.08 d (6.4)</td>
<td>1.10 d (6.4)</td>
</tr>
<tr>
<td>28</td>
<td>104.8</td>
<td>104.4</td>
</tr>
<tr>
<td></td>
<td>4.43 d (8.0)</td>
<td>4.45 d (7.6)</td>
</tr>
<tr>
<td>2’</td>
<td>80.7</td>
<td>80.2</td>
</tr>
<tr>
<td></td>
<td>3.79 m</td>
<td>3.83 m</td>
</tr>
<tr>
<td>3’</td>
<td>75.3</td>
<td>74.8</td>
</tr>
<tr>
<td></td>
<td>3.67 m</td>
<td>3.67 m</td>
</tr>
<tr>
<td>4’</td>
<td>70.1</td>
<td>69.8</td>
</tr>
<tr>
<td></td>
<td>3.85 m</td>
<td>3.86 m</td>
</tr>
<tr>
<td>5’</td>
<td>76.2</td>
<td>75.9</td>
</tr>
<tr>
<td></td>
<td>3.49 m</td>
<td>3.50 m</td>
</tr>
<tr>
<td>6’</td>
<td>62.3</td>
<td>62.2</td>
</tr>
<tr>
<td></td>
<td>3.71</td>
<td>3.71 m</td>
</tr>
<tr>
<td>1’</td>
<td>105.9</td>
<td>105.4</td>
</tr>
<tr>
<td></td>
<td>4.57 d (7.4)</td>
<td>4.57 d (7.6)</td>
</tr>
<tr>
<td>2’</td>
<td>73.2</td>
<td>72.1</td>
</tr>
<tr>
<td></td>
<td>3.62 m</td>
<td>3.64 m</td>
</tr>
<tr>
<td>3’</td>
<td>74.8</td>
<td>74.4</td>
</tr>
<tr>
<td></td>
<td>3.50 m</td>
<td>3.51 m</td>
</tr>
<tr>
<td>4’</td>
<td>70.1</td>
<td>69.8</td>
</tr>
<tr>
<td></td>
<td>3.85 m</td>
<td>3.82 m</td>
</tr>
<tr>
<td>5’</td>
<td>77.0</td>
<td>76.6</td>
</tr>
<tr>
<td></td>
<td>3.52 m</td>
<td>3.54 m</td>
</tr>
<tr>
<td>6’</td>
<td>62.2</td>
<td>62.3</td>
</tr>
<tr>
<td></td>
<td>3.70 m</td>
<td>3.72 m</td>
</tr>
</tbody>
</table>
galactopyranosyl-(1→2)-β-D-galactopyranosyl]-23β-hydroxy-4α-methyl-5α-cholesta-8,14-diene.

The absolute configuration of eryloside A, which had never been fully characterized, was determined using the modified Mosher's method.\textsuperscript{21} Compound 1 was hydrolyzed with HCl to afford the aglycon (19), which was converted to the (R)- and (S)-MTPA diesters (20a,b). Interpretation of δ\textsubscript{δ} values (Figure 3.1) allowed the absolute configuration of C-3 and C-23 to be assigned as 3S and 23S, respectively. This is in agreement with other sponge-derived steroidal glycosides for which the absolute configurations have been determined,\textsuperscript{22,23} as well as cholesterol and ergosterol.\textsuperscript{21}

![Figure 3.1](image)

**Figure 3.1** Distribution of δ\textsubscript{δ} values (Hz) for the MTPA esters of 19.
Eryloside K (2) had the molecular formula of C_{40}H_{64}O_{12}, which was determined by high resolution MALDI-MS (m/z 759.4320; [M+Na]^+) and analysis of $^{13}$C NMR data. Careful analysis of the $^{13}$C NMR and multiplicity-edited HSQC spectra showed that 2 contained six methyl, ten methylene, eighteen methine, and six quaternary carbons (Table 3.2). Chemical shifts indicated that two of the methylene and ten of the methine carbons were associated with two sugar units, and that the remaining twenty-eight carbons belonged to the steroidal portion. Four quaternary and two methine carbons were associated with three double bonds ($\delta_C$ 124.1, 141.6, 152.1, 117.8, 130.2, 133.3), while two of the remaining steroid methines were oxygenated ($\delta_C$ 87.4, 66.3). A major portion of the tetracyclic backbone was assembled through interpretations of HMBC correlations from two methyl singlets ($\delta_H$ 0.86, 1.04), a methyl doublet ($\delta_H$ 1.10) and an olefinic methine ($\delta_H$ 5.34) to ring junction carbons (Me-18 to C-14; Me-19 to C-5, C-9; Me-28 to C-5; H-15 to C-8, C-13). Additional HMBC correlations from the methyl signals established all carbons two and three bonds removed from the methyls. Analysis of the COSY and TOCSY data allowed for assignment of the C-1/C-2/C-3/C-4/C-28/C-5/C-6/C-7, C-11/C-12, and C-15/C-16/C-17 spin systems.

The UV spectrum for 2 suggested the presence of a chromophore derived from a conjugated diene system ($\lambda_{max}$ 249 nm). Whereas one double bond ($\delta_C$ 130.2, 133.3) was shown by COSY and HMBC experiments to be on the side-
Table 3.2 $^{13}$C (100 MHz, MeOH-d$_4$), $^1$H (300 MHz, MeOH-d$_4$), and HMBC (300 MHz, MeOH-d$_4$) NMR data for compound 2.

<table>
<thead>
<tr>
<th>C#</th>
<th>$^{13}$C NMR in ppm</th>
<th>$^1$H NMR in ppm, mult. (J in Hz)</th>
<th>HMBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36.3 CH$_2$</td>
<td>1.28 m</td>
<td>C-10, C-19</td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>1.87 m</td>
<td>C-10, C-19</td>
</tr>
<tr>
<td>2</td>
<td>30.6 CH$_2$</td>
<td>1.62 m</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>2.14 m</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>87.4 CH</td>
<td>3.16 dt (10.7, 5.1)</td>
<td>C-4, C-28, C-1'</td>
</tr>
<tr>
<td>4</td>
<td>38.8 CH</td>
<td>1.51 dd (10.8, 11.2)</td>
<td>C-3, C-5, C-28</td>
</tr>
<tr>
<td>5</td>
<td>48.7 CH</td>
<td>1.07 ddd (12.2, 11.4, 2.4)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>21.6 CH$_2$</td>
<td>1.30 m</td>
<td>C-5, C-7</td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>1.86 m</td>
<td>C-7, C-8</td>
</tr>
<tr>
<td>7</td>
<td>27.7 CH$_2$</td>
<td>2.12 m</td>
<td>C-5, C-8, C-9</td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>2.25 m</td>
<td>C-8, C-9</td>
</tr>
<tr>
<td>8</td>
<td>124.1 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>141.6 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>37.8 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>22.6 CH$_2$</td>
<td>2.21 m</td>
<td>C-13</td>
</tr>
<tr>
<td>12</td>
<td>38.2 CH$_2$</td>
<td>1.36 m</td>
<td>C-11, C-13, C-17, C-18</td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>2.06 m</td>
<td>C-11, C-13, C-18</td>
</tr>
<tr>
<td>13</td>
<td>46.3 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>152.1 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>117.8 CH</td>
<td>5.34 s</td>
<td>C-8, C-13, C-16, C-17</td>
</tr>
<tr>
<td>16</td>
<td>36.7 CH$_2$</td>
<td>2.11 m</td>
<td>C-14, C-15, C-17, C-20</td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>2.36 m</td>
<td>C-13, C-14, C-15, C-17</td>
</tr>
<tr>
<td>17</td>
<td>59.0 CH</td>
<td>1.46 m</td>
<td>C-12, C-13, C-16, C-18, C-20</td>
</tr>
<tr>
<td>18</td>
<td>15.9 CH$_3$</td>
<td>0.86 s</td>
<td>C-12, C-13, C-14, C-17</td>
</tr>
<tr>
<td>19</td>
<td>19.2 CH$_3$</td>
<td>1.04 s</td>
<td>C-1, C-5, C-9, C-10</td>
</tr>
<tr>
<td>20</td>
<td>31.6 CH</td>
<td>1.87 m</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>19.2 CH$_3$</td>
<td>1.02 d (6.8)</td>
<td>C-17, C-20, C-22</td>
</tr>
<tr>
<td>22</td>
<td>45.0 CH$_2$</td>
<td>1.00 m</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CH$_2$</td>
<td>1.66 m</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>66.3 CH</td>
<td>4.42 m</td>
<td>C-23</td>
</tr>
<tr>
<td>24</td>
<td>130.2 CH</td>
<td>5.17 dt (8.4, 1.2)</td>
<td>C-22, C-26, C-27</td>
</tr>
<tr>
<td>25</td>
<td>133.3 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>25.6 CH$_3$</td>
<td>1.70 d (1.2)</td>
<td>C-24, C-25, C-27</td>
</tr>
<tr>
<td>27</td>
<td>17.8 CH$_3$</td>
<td>1.67 d (1.2)</td>
<td>C-26</td>
</tr>
<tr>
<td>28</td>
<td>15.7 CH$_3$</td>
<td>1.10 d (6.4)</td>
<td>C-3, C-4, C-5</td>
</tr>
<tr>
<td>1'</td>
<td>104.5 CH</td>
<td>4.45 d (8.0)</td>
<td>C-3, C-2', C-3', C-5', C-1''</td>
</tr>
<tr>
<td>2'</td>
<td>80.2 CH</td>
<td>3.81 m</td>
<td>C-1', C-1''</td>
</tr>
<tr>
<td>3'</td>
<td>74.9 CH</td>
<td>3.65 m</td>
<td>C-2'</td>
</tr>
<tr>
<td>4'</td>
<td>69.8 CH</td>
<td>3.85 m</td>
<td>C-2'</td>
</tr>
<tr>
<td>5'</td>
<td>76.1 CH</td>
<td>3.50 m</td>
<td>C-1', C-3', C-4', C-6'</td>
</tr>
<tr>
<td>6'</td>
<td>62.2 CH$_2$</td>
<td>3.71 m</td>
<td>C-4'</td>
</tr>
<tr>
<td>1''</td>
<td>105.9 CH</td>
<td>4.58 d (7.6)</td>
<td>C-2'', C-2'', C-3''</td>
</tr>
<tr>
<td>2''</td>
<td>72.8 CH</td>
<td>3.62 m</td>
<td>C-1'', C-3''</td>
</tr>
<tr>
<td>3''</td>
<td>74.5 CH</td>
<td>3.49 m</td>
<td>C-1''</td>
</tr>
<tr>
<td>4''</td>
<td>69.8 CH</td>
<td>3.85 m</td>
<td>C-2'', C-3'', C-6''</td>
</tr>
<tr>
<td>5''</td>
<td>76.8 CH</td>
<td>3.53 m</td>
<td>C-2'', C-4'', C-6''</td>
</tr>
<tr>
<td>6''</td>
<td>62.3 CH$_2$</td>
<td>3.72 m</td>
<td>C-4'', C-5''</td>
</tr>
</tbody>
</table>
chain of the steroid, the remaining diene appeared to be within the tetracyclic ring system. Since three of the four olefinic carbons were quaternary, only two locations for a conjugated system were possible: \( \Delta^8,14 \) and \( \Delta^9(11),8(14) \). Comparison with \( ^{13}C \) NMR values for 5α-cholesta-8,14-dien-3β-ol\(^24\) and 3β-hydroxy-5α-cholesta-8(14),9(11)-dien-15-one\(^25\) allowed the elimination of the \( \Delta^9(11),8(14) \) system and established the 8,14 diene as the correct location.

A comparison of the HSQC spectra for 2 and 1 suggested differences in their side-chain substituents (Figure 3.2). HMBC correlations from H-17 (\( \delta_H \) 1.46) to C-20 (\( \delta_C \) 31.6) established attachment of the side-chain at C-17. An HMBC correlation from Me-21 (\( \delta_H \) 1.02) to C-22 (\( \delta_C \) 45.0), along with COSY correlations between H2-22 (\( \delta_C \) 1.00, 1.66), H-23 (\( \delta_H \) 4.42) and H-24 (\( \delta_H \) 5.17), firmly established the configuration of the side-chain, including the C-23 allylic alcohol and the C-24/C25 alkene. The side-chain methyl doublets at \( \delta \) 1.70 and 1.67 were assigned to the vinyl methyl groups at C-26 and C-27 respectively, on the basis of HMBC correlations to the fully substituted olefinic carbon at C-25 (\( \delta_C \) 133.3) and the olefinic methine at C-24 (\( \delta_C \) 130.2). Analysis of the \(^{13}C\) NMR data further supported the presence of a double bond in 2 that was not present in 1 (Figure 3.3).

The identity and arrangement of the glycon moiety was established by a combination of 1D and 2D NMR experiments. The \(^{13}C\) NMR shifts of the anomeric methine carbons (\( \delta_C \) 104.5, 105.9) suggested that both sugars were
Figure 3.2 Enlargement of the upfield region of the HSQC spectra for compounds (a) 1, (b) 2, and (c) 3. Direct proton-carbon coupling can be used to differentiate between these related analogs. Numbers and arrows indicate chemical shifts of side-chain protons. Note that other (non-side chain) shifts do not change between compounds.
Figure 3.3 Comparison of the downfield region of $^{13}$C NMR spectra for 1 (top) and 2 (bottom). Arrow indicates the appearance of two signals due to the presence of the side-chain olefin in 2. Truncated portion of the molecules shown for clarity.
connected through β-glycosidic linkages. An HMBC correlation between H-3α (δ_H 3.16) and C-1’ (δ_C 104.5) established the location of the glycosidic linkage at C-3, and a correlation from H-2’ to C-1” defined the linkage between the two sugar units. This latter finding was supported by an observed NOE between H-2’ (δ_H 3.81) and H-1” (δ_H 4.58). Comparison of the COSY data and proton J-values with the literature established both sugars as β-galactopyranoside units.

The relative stereochemistry of the steroidal portion of 2 was assigned on the basis of NOE enhancements (Figure 3.4) and ^1H-^1H coupling constants. Observed 1,3-diaxial NOE correlations between Me-19, H-2β (δ_H 1.62), H-4β (δ_H 1.51), and H-6β (δ_H 1.86) established the chair conformation and the trans-ring fusion of the A and B rings, as well as the axial orientation of Me-19 and the 10S^* stereochemistry for C-10. The 4α-methyl configuration was determined by a large diaxial coupling (J = 10.7) between H-3α (δ_H 3.16) and H-4β (δ_H 1.51). Since the H-5 ^1H NMR signal was obscured by the Me-28 doublet (δ_H 1.10), a 1D TOCSY experiment was used to determine the 11.2-Hz diaxial coupling constant between H-4β and H-5 (δ_H 1.07). This established the α position for H-5, as well as the 4S^* and 5R^* stereochemistries at C-4 and C-5. It was not possible to distinguish the H2-11 methylene signals (δ_H 2.21) by ^1H NMR, making it difficult to determine the orientation of Me-18. However, the axial orientation of Me-18 was assignable based on NOE enhancements from Me-18 to both Me-21 (δ_H 1.02) and H-20.
Figure 3.4 NOE correlations for the steroidal portion of 2.

(δH 1.87). In addition, a long-range COSY correlation between Me-18 and H-12α suggested that both groups were axial. Finally, the β-orientation for the side-chain could be assigned based on an NOE between H-12α (δH 1.36) and H-17 (δH 1.46). The relative stereochemistries at C-13 and C-17 were thus established as 13R* and 17R*. Eryloside K is a 3β-O-({β-D-galactopyranosyl-(1→2)-β-D-galactopyranosyl}-23β-hydroxy-4α-methyl-5α-cholesta-8,14,24-triene.

Eryloside L (3) had a molecular formula of C₄₀H₆₄O₁₂, which was determined by high-resolution MALDI-MS (m/z 759.4283; C₄₀H₆₄O₁₂ Na) and by interpretation of the ¹³C NMR data. The spectral data of 3 were very similar to
those of 1 and 2. Careful examination of the $^1$H and $^{13}$C NMR data (Table 3.1) revealed that both the disaccharide chain and the tetracyclic backbone were conserved in 3, but an analysis of the HSQC spectrum suggested an alteration in the alkyl side-chain (Figure 3.2). Unlike 1 and 2, 3 lacked a side-chain hydroxyl group. The presence of a strongly deshielded $^{13}$C signal ($\delta_C$ 213.3), combined with an IR band at 1705 cm$^{-1}$ and a downfield alpha methylene signal ($\delta_H$ 2.32), suggested the presence of a side-chain ketone. HMBC correlations from the carbonyl carbon to H$_2$-22 and H$_2$-24 established the location of the ketone at C-23. Thus, 3 has been assigned as 3$\beta$-$O$-{$\beta$-$D$-galactopyranosyl}(1$\rightarrow$2)-{$\beta$-$D$-galactopyranosyl)-4$\alpha$-methyl-5$\alpha$-cholesta-8,14-dien-23-one.

To establish the absolute configuration for eryloside K, I attempted to obtain the aglycon of 2 via acid hydrolysis. Not surprisingly, the allylic alcohol readily dehydrated upon exposure to HCl or milder acids. To circumvent this problem, I decided to reduce the side-chain alkene in 2 and compare the properties of the resulting product to the product of 1 when exposed to the same conditions. Rhodium was chosen as the catalyst since it is known to minimize hydrogenolysis of allylic alcohols.$^{27}$ Hydrogenation of both 1 and 2 in the presence of 5% rhodium catalyst yielded compound 21 (Figure 3.5), in which the C-24/25 alkene (2) and the C-14/15 alkene (1 and 2) were reduced, while the more highly substituted C-8/9 alkene remained intact. The resulting products exhibited identical $^1$H NMR spectra, optical rotations, and HPLC retention times.
(Figure 3.6). Eryloside K must therefore have the same absolute configuration as 1.\textsuperscript{28} Eryloside L also has the same absolute stereochemistry as 1 and 2 based on similarities in optical rotation and biogenetic reasoning.

**Biological Activity**

Glycosylated marine natural products tend to exhibit potent and/or selective bioactivity.\textsuperscript{29} The erylosides have been reported with anticancer, antifungal, and anticoagulative activity,\textsuperscript{16-20} and erylosides A, K, and L all exhibited selective cytotoxicity against a \textit{\Delta rad50} yeast strain deficient in DSB repair. Modifications in the side-chain between 1, 2, and 3 corresponded to noticeable differences in both the potency and selectivity of the erylosides against the yeast strains (Table 3.3). The aglycon (19) did not exhibit significant activity against any of the yeast strains, suggesting that glycosylation of these molecules is integral to their bioactivity.

In order to determine if the erylosides caused cell-cycle arrest in yeast, wildtype cells were exposed to eryloside A (1) and monitored by microscopy. \textit{S. cerevisiae} divides by budding, and the cell-cycle stage of an actively dividing cell can be determined by examining the size of the bud and the number of DNA copies. Cells treated with a sublethal dose of 1 (8.5 \textmu M) were fixed and DAPI stained every hour. When DAPI binds to DNA, its fluorescence is strongly enhanced, allowing me to assess the number of DNA copies in each cell by
Figure 3.5 Catalytic hydrogenation of 1 and 2.
Figure 3.6 HPLC chromatograms of hydrogenation products from (a) 1 and (b) 2. Double-sided arrow indicates peak associated with compound 21. Phenomenex Luna C18 column; 46% CH3CN; detected at 254 nm; tR = 12.6 minutes.
Table 3.3 Activity\(^a\) of erylosides and some reference topoisomerase poisons against different yeast strains\(^b\).

<table>
<thead>
<tr>
<th>Compound</th>
<th>Parent</th>
<th>Arad50(^c)</th>
<th>TOP1oe(^d)</th>
<th>TOP2oe(^e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eryloside A (1)</td>
<td>3.5</td>
<td>0.8</td>
<td>5.7</td>
<td>10.8</td>
</tr>
<tr>
<td>Eryloside K (2)</td>
<td>6.1</td>
<td>2.0</td>
<td>7.5</td>
<td>12.2</td>
</tr>
<tr>
<td>Eryloside L (3)</td>
<td>11.4</td>
<td>3.4</td>
<td>10.9</td>
<td>9.5</td>
</tr>
<tr>
<td>Aglycon (4)(^f)</td>
<td>&gt;50</td>
<td>&gt;50</td>
<td>NT(^f)</td>
<td>NT</td>
</tr>
<tr>
<td>Camptothecin (7)(^f)</td>
<td>3.8</td>
<td>0.1</td>
<td>0.4</td>
<td>1.5</td>
</tr>
<tr>
<td>Idarubicin (9)(^f)</td>
<td>3.5</td>
<td>0.2</td>
<td>3.5</td>
<td>0.2</td>
</tr>
</tbody>
</table>

\(^a\) IC\(_{50}\) (µM).

\(^b\) Log-phase culture of *S. cerevisiae* strains (135 µL, OD\(_{600}\) of 0.5) treated with serial dilution of drug or DMSO (15 µL) for 18 hours and optical density monitored (n=3).

\(^c\) *S. cerevisiae* strain with a deletion in the rad50 gene.

\(^d\) *S. cerevisiae* strain overexpressing topoisomerase I enzyme.

\(^e\) *S. cerevisiae* strain overexpressing topoisomerase II enzyme.

\(^f\) Indicates not tested.

\(^f\) See reference.\(^3\)
microscopy. In comparison with untreated controls, the number of treated cells in G\textsubscript{1} phase slightly increased with time (Figure 3.7), suggesting that I may have been causing cell-cycle arrest at this stage. G\textsubscript{1} is a critical point at which the cell assesses whether it should enter another full round of cell division. Proteins involved in G\textsubscript{1} progression are frequently mutated in human cancers and are among the most attractive targets for the development of new anticancer drugs.\textsuperscript{30} Rapamycin (22) and wortmannin (23) are two well-known examples of bioactive natural product that cause G\textsubscript{1}-specific arrest.

Several studies have suggested that selective cytotoxicity against yeast mutants deficient in DSB repair may be an indicator of topoisomerase poisons.\textsuperscript{3,31} Topoisomerase inhibitors such as camptothecin (7) and idarubicin (9), exhibit marked selectivity against DSB repair mutants (Table 3.3). Topo I and topo II poisons can be distinguished by selective cytotoxicity against yeast strains overexpressing TOP1 and TOP2 respectively, as compared to a wild-type yeast strain.\textsuperscript{3} Based on this, compounds 1-3 do not appear to be topoisomerase poisons (Table 3.3). In addition, 1-3 failed to stabilize the covalent complex between DNA and human topoisomerase I or II when screened for DNA strand-break activity\textsuperscript{32} at a dose of 500 μM (Figure 3.8).

In contrast, results obtained from the National Cancer Institute 60-cell line antitumor assay suggested that 1-3 may be topoisomerase II inhibitors. Analysis of the assay data was performed using the COMPARE algorithm,\textsuperscript{33} which ranks
the bioactivity profile of the test compound according to similarity with 175 standard anticancer drugs. The results obtained by analyzing 60-cell line data with COMPARE often reflect the mechanism of action by which chemical substances act upon cells. Since COMPARE does not use chemical data in its analysis, it can detect structurally novel compounds that act by known mechanisms. As a result, novel classes of compounds can be recognized as topoisomerase I or II agents, tubulin-binding agents, or inhibitors of protein synthesis. A COMPARE analysis of eryloside K (2) revealed that it correlated principally with etoposide (10) and the anthracycline analog morpholino-ADR (24), both selective topo II inhibitors (Table 3.4). Similarly, eryloside L (3) correlated highly with three anthracycline analogs (25-27).

The primary mode of action for anthracyclines such as 24-27 is believed to be their reversible binding to nucleolar DNA, which causes inhibition of the replication process and thence death. Numerous biochemical studies including evidence from NMR spectroscopic and X-ray crystallographic studies have shown that these compounds intercalate into double-stranded DNA with guanine-cytosine site-specific interactions. The base pairs above and below the drug 'buckle' in conformation to afford a distorted DNA helix, thereby preventing association with the DNA helicase, DNA topoisomerase and polymerase enzymes. Despite the fact that the erylosides lack TOP2 cleavage activity in a DNA strand-break assay, COMPARE analysis suggests that these compounds exhibit a similar (albeit weaker) mechanism of action with known topo II poisons.
Figure 3.7 Effect of compound 1 on cell cycle of wild type yeast: (a) Cells treated with 6.25 µg/ml (8.5 µM) of 1 and (b) untreated control cells (n=200). □ = no bud (G1-phase); ◊ = small bud (S-phase); ■ = large bud, 1 nucleus or mitotic (G2/M-phase); ▼ = large bud, 2 nuclei (M-phase); ▼ = missegregated/ messy DNA.
Figure 3.8 Effects of compounds 1-3 on (a) topoisomerase I and (b) topoisomerase II. Lanes 1 = untreated supercoiled (sc) DNA; Lane 2 = TOP1 + scDNA; Lane 3 = topo I poison (topotecan) + TOP1 + scDNA; Lane 4 = 1 + TOP1 + scDNA; Lane 5 = 2 + TOP1 + scDNA; Lane 6 = 3 + TOP1 + scDNA; Lane 7 = scDNA; Lane 8 = TOP2 + scDNA; Lane 9 = topo II poison (etoposide; 200 μM) + TOP2 + scDNA; Lane 10 = 1 + TOP2 + scDNA; Lane 11 = 2 + TOP2 + scDNA; Lane 12 = 3 + TOP2 + scDNA. Unless otherwise noted, 500 μM of each compound was used.
Table 3.4 Results from COMPARE analysis of compounds 1-3.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Rank</th>
<th>Correlation*</th>
<th>Compound</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eryloside A (1)</td>
<td>1</td>
<td>0.422</td>
<td>Didemnin B</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.411</td>
<td>Thaliblastine</td>
<td>Cell membrane</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.359</td>
<td>Acivicin</td>
<td>Glutamine amidotransferase</td>
</tr>
<tr>
<td>Eryloside K (2)</td>
<td>1</td>
<td>0.522</td>
<td>Morpholino-ADR (24)</td>
<td>Topo II</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.348</td>
<td>Etoposide (10)</td>
<td>Topo II</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.298</td>
<td>Floxuridine</td>
<td>DNA synthesis</td>
</tr>
<tr>
<td>Eryloside L (3)</td>
<td>1</td>
<td>0.425</td>
<td>Dibenzyldaurubicin (25)</td>
<td>Topo II</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.419</td>
<td>Menogaril (26)</td>
<td>Topo II</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.359</td>
<td>MX2-HCl (27)</td>
<td>Topo II</td>
</tr>
</tbody>
</table>

*The correlation coefficient can range from -1 to +1, with -1 indicating a perfect negative correlation, +1 indicating a perfect positive correlation.
There is further evidence to suggest that the erylosides inhibit topoisomerase II. In 2000, Abdel-Kader et al. isolated a series of chemically related metabolites from a tropical plant species.\textsuperscript{36} Interestingly, this class of steroidal glycosides was reported to have selective cytotoxicity against a panel of yeast mutants deficient in topoisomerase function. The panel consisted of three strains (1138, 1140, and 1353), and topo II inhibitors were distinguished as those compounds that inhibited strain 1138 only. Three of the compounds (28-30) exhibited two-fold or greater inhibition of strain 1138 than the other strains, suggesting that these compounds are topo II inhibitors.

The erylosides are not the first examples of selective topoisomerase inhibitors being isolated from a marine invertebrate. Kalihinol F (31), a naturally occurring diterpene from a marine sponge \textit{Acanthella} sp., inhibited topoisomerase I activity in vitro, but had no effects on activities of DNA polymerases alpha, beta, and gamma, and of topoisomerase II.\textsuperscript{37} Ascididemin (32), a pyridoacridine alkaloid from the Okinawan tunicate \textit{Didemnum} sp., was shown to exhibit potent DNA cleavage activity.\textsuperscript{38,39} Relaxation assays using supercoiled DNA showed that 32 stimulated double-stranded cleavage of DNA by topoisomerase II, but exerted only a very weak effect on topoisomerase I.\textsuperscript{40} Other pyridoacridine alkaloids have also been shown to target topoisomerase II.\textsuperscript{41}

This work has validated the use of a simple, cell-based assay to rapidly identify and isolate selectively bioactive compounds from a crude marine extract. The structural determination of two compounds (2 and 3), along with the absolute
configuration of the known compound 1 provides an important addition to the knowledge of this unique class of secondary metabolites. Although the precise molecular mechanism of action has not been determined, it is reasonable to assume that these compounds are weakly selective inhibitors of human topoisomerase II, an important target in the fight against cancer. One must not overlook the possibility that the saponic nature of these compounds contributes to their ability as selectively cytostatic or cytotoxic agents (i.e. as surfactants). However, this does not explain the selective bioactivity profiles observed from the multiple, independently monitored investigations mentioned above. Well-known surfactants, such as the triton-X 100 detergent, do not exhibit any selectivity against yeast mutants deficient in DSB repair (J. Simon, pers. comm.).

$$\text{28} \quad R_1 = \text{H}; R_2 = \text{H}$$

$$\text{29} \quad R_1 = \text{xylose}; R_2 = \text{glucose}$$

$$\text{30} \quad R_1 = \text{glucose}; R_2 = \text{glucose}$$

$$\text{31}$$

$$\text{32}$$
The text of this chapter is, in part, a reprint of the material as it appears in Tetrahedron 2005, 61, 1199-1206 with co-authors Susan L. Forsburg and D. John Faulkner. I was the primary researcher and author, and the co-authors listed in this publication helped direct and supervise the research, which forms the basis of this chapter.

**Experimental**

**General Methods.** Optical rotations were measured on a Rudolf Autopol III polarimeter at 598 nm. IR spectra were recorded on a Perkin-Elmer 1600 FT-IR spectrophotometer. UV spectra were obtained using a Perkin-Elmer Lambda Bio-20 spectrophotometer. $^1$H, COSY, HMBC, HSQC, 1D-NOESY, 1D-TOCSY, and ROESY NMR spectra were measured on a Varian Inova 300 MHz spectrometer. $^{13}$C and DEPT spectra were measured on a Varian Gemini 400 MHz spectrometer. ESI MS spectra were recorded using a Finnigan LCQ mass spectrometer. High-resolution MALDI-MS data were obtained on a PE Biosystems DE-STR MALDI TOF system at the U.C. Riverside Regional Facility. All solvents were distilled prior to use.

**Extraction and Purification.** The sponge *Erylus lendenfeldi* was collected by SCUBA in February, 2000 in the Red Sea just north of Hurghada. The crude methanol extract exhibited selective cytotoxicity against a *Δrad50* yeast strain, and was thus selected for further study. A portion of the freeze-dried sponge (180
g) was extracted three times in methanol to give 1 L of crude extract. Roughly half of the methanol was removed in vacuo, and the remaining extract was partitioned on HP20 (Supelco Diaion®) using an increasing concentration of acetone in water. The 50% aqueous acetone fraction (200 mg) exhibited the most potent and selective activity against Δrad50 mutants and was thus purified using reversed-phase HPLC (Dynamax C8 semi-prep, 75% MeOH, 3 mL/min) to give eryloside A (1, 720 mg, 0.4% dry weight), eryloside K (2, 145 mg, 0.08% dry weight), and eryloside L (3, 90 mg, 0.05% dry weight).

**Eryloside A (1):** white powder; [α]D +6° (c 1.11, MeOH); mp: 168-172°C; UV (MeOH) λmax (log ε) 250 (4.24); IR νmax (MeOH) 3360, 2930, 1060 cm⁻¹; ¹H NMR (400 MHz, CD3OD) see Table 3.1; ¹³C NMR (100 MHz, CD3OD) see Table 3.1; HRMALDI-MS m/z 761.4472 ([M+Na]⁺ calcd for C40H66O12Na, 761.45543).

**Eryloside K (2):** white powder; [α]D +10° (c 0.12, MeOH); mp: 208-212°C; UV (MeOH) λmax (log ε) 249 (4.31); IR νmax (MeOH) 3400, 2925, 1380, 1060 cm⁻¹; ¹H NMR (400 MHz, CD3OD) see Table 3.2; ¹³C NMR (100 MHz, CD3OD) see Table 3.2; HRMALDI-MS m/z 759.4320 ([M+Na]⁺ calcd for C40H64O12Na, 759.4290).

**Eryloside L (3):** white powder; [α]D +10° (c 0.34, MeOH); mp: 200-204°C; UV (MeOH) λmax (log ε) 250 (4.33); IR νmax (MeOH) 3375, 2930, 1705, 1370, 1060 cm⁻¹; ¹H NMR (400 MHz, CD3OD) see Table 3.1; ¹³C NMR (100 MHz, CD3OD)
see Table 3.1; HRMALDI-MS m/z 759.4283 ([M+Na]^+ calcd for C_{40}H_{64}O_{12}Na, 759.4290).  

**Acid Hydrolysis of Eryloside A (1):** A portion of 1 (90 mg) was dissolved in 9 mL of a 1:1:48 mixture of HCl:benzene:EtOH and stirred at 65°C. After 3 hours, the mixture was neutralized with NaCO₃. The filtered slurry was dried down *in vacuo*, and the purified aglycon (19) was obtained in roughly quantitative yield by silica gel chromatography eluting with ethyl acetate.

19: ^1^H NMR (CD₃OD) δH 0.84 (3H, s, H-18), 0.91 (3H, d, H-26), 0.91 (3H, d, H-27), 0.97 (3H, d, H-21), 0.98 (3H, d, H-28), 1.01 (3H, s, H-19), 1.01 (1H, m, H-22a), 1.06 (1H, m, H-5), 1.15 (1H, m, H-24a), 1.27 (1H, m, H-1a), 1.32 (1H, m, H-6a), 1.34 (1H, m, H-4), 1.38 (1H, m, H-24b), 1.38 (1H, m, H-12a), 1.47 (1H, m, H-17), 1.51 (1H, m, H-22b), 1.54 (1H, m, H-2a), 1.76 (1H, m, H-25), 1.84 (1H, m, H-2b), 1.86 (1H, m, H-6b), 1.90 (1H, m, H-1b), 1.94 (1H, m, H-20), 2.06 (1H, m, H-12b), 2.10 (1H, m, H-16a), 2.14 (1H, m, H-7a), 2.22 (2H, m, H-11), 2.25 (1H, m, H-7b), 2.32 (1H, m, H-16b), 3.02 (1H, m, H-3), 3.75 (1H, m, H-23), 5.33 (1H, s, H-15); ESIMS m/z 415 (M+H)^+.

**MTPA esterification of 19:** To a solution of 14.5 mg of 4 in 250 μL dry DCM and 28 μL pyridine was added 200 μL of (S)-MTPACl. The mixture was stirred over an ice bath for 4 hours. After the consumption of the starting material was confirmed by TLC, the solution was twice washed with 5% aq. NaHCO₃. The organic phase was dried under N₂ and chromatographed on silica gel (95:5
CHCl₃/MeOH) to give 5.2 mg of 20a. Using the same procedure, 200 µL of (R)-MTPACl and 14.5 mg of 19 were reacted to obtain 3.8 mg of 20b.

20a: $^1$H NMR (CD$_3$OD) $\delta$H 0.64 (3H, s, H-18), 0.92 (3H, d, H-26), 0.96 (3H, d, H-27), 0.90 (3H, d, H-21), 0.98 (3H, s, H-19), 1.22 (1H, m, H-1a), 1.14 (1H, m, H-5), 1.23 (1H, m, H-6a), 1.34 (3H, d, H-28), 1.38 (1H, m, H-12a), 1.43 (1H, m, H-24a), 1.43 (1H, m, H-20), 1.57 (1H, m, H-25), 1.60 (1H, m, H-17), 1.62 (1H, m, H-22a), 1.65 (1H, m, H-24b), 1.69 (1H, m, H-2a), 1.72 (1H, m, H-6b), 1.72 (1H, m, H-22b), 1.97 (1H, m, H-1b), 2.02 (1H, m, H-12b), 2.04 (1H, m, H-4), 2.05 (1H, m, H-16a), 2.09 (1H, m, H-2b), 2.20 (2H, m, H-11), 2.20 (1H, m, H-7a), 2.38 (1H, m, H-16b), 2.55 (1H, m, H-7b), 4.6 (1H, m, H-3), 5.34 (1H, m, H-23), 5.53 (1H, s, H-15).

20b: $^1$H NMR (CD$_3$OD) $\delta$H 0.78 (3H, s, H-18), 0.86 (3H, d, H-26), 0.88 (3H, d, H-27), 0.91 (3H, d, H-21), 0.93 (3H, s, H-19), 1.23 (1H, m, H-1a), 1.23 (1H, m, H-5), 1.24 (1H, m, H-6a), 1.31 (1H, m, H-24a), 1.37 (3H, d, H-28), 1.40 (1H, m, H-12a), 1.45 (1H, m, H-20), 1.47 (1H, m, H-25), 1.54 (1H, m, H-2a), 1.57 (1H, m, H-24b), 1.67 (1H, m, H-17), 1.72 (1H, m, H-22a), 1.75 (1H, m, H-6b), 1.81 (1H, m, H-22b), 1.87 (1H, m, H-1b), 2.00 (1H, m, H-2b), 2.05 (1H, m, H-4), 2.06 (1H, m, H-12b), 2.10 (1H, m, H-16a), 2.21 (2H, m, H-11), 2.22 (1H, m, H-7a), 2.44 (1H, m, H-16b), 2.60 (1H, m, H-7b), 4.58 (1H, m, H-3), 5.37 (1H, m, H-23), 5.55 (1H, s, H-15).
Catalytic Hydrogenation Product 21: Compounds 1 and 2 (10 mg) were each dissolved in 10 ml of MeOH. Hydrogenation was effected under H₂ gas (~3 atm) in the presence of 5% rhodium on Al₂O₃. The reaction was complete after 50 minutes as indicated by TLC. The filtered slurry was dried to give the identical product (21) in both cases. Products from hydrogenation reactions using 1 and 2 had identical masses (ESIMS, m/z 764 [M+Na]) corresponding to the reduction of one double bond in 1, and two double bonds in 2. The products from 1 and 2 had similar optical rotation values of [α]D = +12.4° (c 0.20, MeOH) and [α]D = +12.3° (c 0.21, MeOH) respectively, the same ¹H NMR spectra (data not shown), and identical HPLC retention times on C8 (Zorbax XDB; 67% MeOH; detected at 254 nm; tR = 20.7 min.) and C18 (Phenomenex Luna; 46% CH₃CN; detected at 254 nm; tR = 12.6 min.).

Yeast Strains. All budding yeast strains were obtained from the Molecular Pharmacology Program at the Fred Hutchinson Cancer Research Center in Seattle, WA. Six strains were used, each with drug-sensitizing mutations that increased membrane porosity (Δerg6)⁴³ and hindered drug efflux (Δpdr1 and Δpdr3).⁴⁴ In addition to these mutations, two of the strains contained a mutation in a double-strand break repair gene (yMP11406; Δrad50)⁴⁵ and a DNA damage checkpoint gene (yMP10605; mec2-1/Δrad53)⁴⁶ respectively. Three other strains contained double mutations in a postreplication repair gene (yMP10425; Δrad18)⁴⁷ and a mismatch repair gene (SP50248; Amlh1)⁴⁸, a nucleotide excision
repair gene (yMP10691; Δradl4) (review in ref. 49) and overexpression of the G1 cyclin CLN2 (CLN2oe) 50, and a 5’ to 3’ helicase gene (SP50265; Δsgs1) 51 and an alkylguanine transferase gene (yMP10612; Δmgt1). 52 The parent strain (yMP10381) was used as a control.

**Yeast Assay.** Exponentially growing yeast in enriched liquid media were diluted to OD600 = 0.07, and 135 μL of cells along with 15 μL of extract in DMSO was dispensed into each well of flat-bottomed 96-well microtiter plates. The assay was conducted in two stages. In stage 1, extracts (50 μg/mL) that produced a 70% or greater inhibition of growth in any or all strains advanced to stage 2. In stage 2, extracts were tested at 50, 25, 12.5, 6.3, 3.1, and 1.6 μg/mL. Extracts that produced a two-fold or greater difference in sensitivity between the most sensitive strain and less sensitive strains were studied further. Plates were incubated on a shaker plate for 18h at 25°C, and the optical density (600 nm) of the cultures was determined using a Bio-Tek Instruments ELx808 microplate reader to assess relative growth. DMSO and cycloheximide were used as negative and positive controls respectively.

**Staining cells for DAPI analysis.** Clean glass slides were coated in 10 μl of 0.01% polylysine for 3 minutes. Excess polylysine was removed and slides were air dried. 150 μl of cell broth from 96-well plate was centrifuged and excess media was removed by aspiration. Cold 70% ethanol (1 ml) was added and solution was vortexed. Ethanol-fixed cells were washed with water (200 μl,
milliQ), and 5 μl of cells were placed on slide. After three minutes, excess cells were aspirated and slide air dried for 5 minutes. Mount media (2 μl) and DAPI® (0.6 μl; 1 mg/ml) were added to slide prior to viewing.

**Staining cells for FACS analysis.** Cell broth (150 μl) from 96-well plate was centrifuged and excess media was aspirated. Cold 70% ethanol (1 ml) was added, solution was vortexed, and centrifuged. Excess ethanol was aspirated, and 1 ml 50mM sodium citrate was added. Cells were vortexed, centrifuged, and sodium citrate was aspirated. Sodium citrate (500 ml; 50 mM) was added, cells were vortexed and transferred to FACS tubes. RNase A (500 ml; 0.5 mg/ml in 50 mM sodium citrate) was added. Cells were incubated at 50°C for 1 hour, centrifuged, and excess supernatant was aspirated. SytoxGreen® (0.5 ml; 2 μM) was added prior to FACS analysis.

**DNA strand-break activity.** *In vitro* assays assessing TOP1- and TOP2-specific activity were conducted as reported previously.\(^{32}\)
References


28. Due to a change in prioritization of groups surrounding the C-23 chiral center, 2 has the 23R configuration while 1 has the 23S configuration.


CHAPTER 4

NOVEL MACROLIDES FROM A NEW DEEP-WATER PALAUAN SPONGE LEIODERMATIUM SP.

An investigation of a new deep-water marine sponge Leiodermatium sp. resulted in the isolation of two novel macrolides, leiodelides A (1) and B (2). The leiodelides represent the first members of a new class of marine-derived macrolides, incorporating several unique functional groups including a conjugated oxazole ring and an $\alpha,\alpha$-hydroxy-methyl carboxylic acid terminus. The structures were established primarily by interpretation of NMR data. A model for the relative stereochemistry of five chiral centers was proposed based on detailed interpretation of spectroscopic data. The leiodelides inhibited the growth of HCT-116 human colon tumor cells at low micromolar concentrations.

Introduction

Lithistid demosponges are a highly prolific source of novel bioactive secondary metabolites and are renowned for their ability to produce a diverse array of polyketides, cyclic peptides, alkaloids, pigments, and novel sterols. The order Lithistida is, in fact, a phylogenetically artificial assemblage of diverse species that all contain fused spicules called desmas. In addition to the physical protection
afforded by these siliceous spicules, lithistids are typically characterized by the presence of potently bioactive secondary metabolites that provide chemical defense against competition, predation, and microbial fouling. The extreme diversity of secondary metabolites found among lithistids defies simple chemotaxonomic reasoning, and symbiotic microorganisms have been shown to be responsible for the production of at least some of these compounds.\textsuperscript{3} Regardless of which organism is the actual producer, lithistid sponges have been a remarkably fruitful source of novel compounds with potent and unique biological activities.

Despite the fact that lithistids are found predominantly in deep-water habitats, chemical investigations have tended to focus on shallow species that are readily accessible by SCUBA. Swinholide A (3) is a potent cytotoxic macrolide that was first isolated by Carmely and Kashman from a Red Sea specimen of \textit{Theonella swinhoei}.\textsuperscript{4} It was originally reported as a monomeric 22-membered macrolide (4), a structure that was supported by NMR data, elemental analysis, and mass spectroscopy. A subsequent study of an okinawan specimen of \textit{T. swinhoei} resulted in the isolation of a macrolide that was spectroscopically identical to swinholide A.\textsuperscript{5} The positive and negative FABMS spectra from this compound, however, showed ion peaks suggesting that swinholide A had a dimeric dilactone structure. The revised structure (3), along with its absolute stereochemistry, was unambiguously proven by X-ray crystallographic analysis.\textsuperscript{6} Swinholide A was shown to disrupt the actin cytoskeleton, sequester actin dimers, and rapidly sever F-actin of cells grown in culture, suggesting that the compound
might be therapeutically useful in certain cancers where filamentous actin contributes to pathology.\(^7\) Callipeltoside A (5) is a cytotoxic glycoside macrolide isolated from a New Caledonian sponge, *Callipelta* sp.\(^8\) Although only moderately cytotoxic, a flow cytometry assay of lung cancer cells treated with 5 revealed the compound induced a cell-cycle dependent cytotoxicity involving arrest during G1 phase. Theoneberine (6) is an unusual alkaloid that was isolated from an unidentified Okinawan *Theonella* sponge.\(^9\) Compound 6 showed moderate cytotoxicity against lymphoma and carcinoma cells, but lacked specificity and was therefore not pursued further. Cyclothreonamides A (7) and B (8) belong to an interesting family of cyclic peptides that contain a rare \(\alpha\)-keto amide functionality. These compounds were shown to potently inhibit thrombin,\(^10\) resulting in anticoagulant activity. The structural elucidation of theonellamide F (9),\(^11\) an antifungal bicyclic peptide from *Theonella* sp., was particularly challenging for its time and paved the way for the characterization of other lithistid metabolites such as theonegramide (10)\(^12\) and theopalauamide (11).\(^13\) Aciculitins A-C (12-14) were obtained from the lithistid sponge *Aciculites orientalis* and inhibited the growth of HCT-116 human colon tumor cells at low micromolar concentrations.\(^14\)

A few interesting compounds have been isolated from deep-water lithistid sponges that were collected by submersible or sea-floor dredging. A particularly noteworthy example is the case of discodermolide (15), a polyhydroxylated lactone from the Atlantic deep-water sponge *Discodermia dissoluta*.\(^15\) While it
was originally reported as a cytotoxic anti-inflammatory compound, 15 was subsequently shown to stabilize microtubules in the same manner as Taxol™ and is now in clinical trials as an anticancer drug. Other interesting compounds from deep-water Discodorina sponges include the discobahamins (16-17) and polydiscamide A (18), an anticancer cyclic peptide. A deep-water Microscleroderma species obtained by sea-floor dredging in New Caledonia contained two antifungal cyclic peptides, microsclerodermins A (19) and B (20). Since their discovery, several other microsclerodermin analogs have been reported. Superstolide A (21) is a unique macrolide that was isolated from a New Caledonian deep-water sponge Neosiphonia superstes. Although superstolide A exhibited potent cytotoxicity against several cancer cell lines, the molecular mode of action of this compound remains undetermined.

Aside from the New Caledonian reefs, the deep-water habitats of the tropical Pacific, including those in Micronesia and Polynesia, have been largely inaccessible and few sponges from these regions have been examined due to the difficulties involved in their procurement. Recently, use of the Deep Worker, a manned submersible, has provided access to the remote depths along the barrier reefs of Palau, providing an unprecedented opportunity to collect new species of lithistid sponges. As part of my ongoing search for anticancer compounds from marine sponges, I examined a specimen of a new deep-water species of lithistid sponge, Leiodermatium sp. No secondary metabolites have been reported from
1 \( R=H \)
22 \( R=\text{Me} \)

1

2

3

4

5

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6

7 \( R = H \)

8 \( R = \text{Me} \)

9
12 \( R = \text{C}_3\text{H}_7 \)
13 \( R = \text{C}_6\text{H}_{13} \)
14 \( R = \text{C}_7\text{H}_{15} \)

15

16 \( R = \text{H} \)
17 \( R = \text{CH}_3 \)
this genus until now. An analysis of the isolation, structural elucidation, and
bioactivity of two novel macrocyclic lactones, leiodelides A (1) and B (2), is
presented below.

**Isolation and structural elucidation**

Using the manned submersible, *Deep Worker 2000*, Patrick Colin collected
the sponge on the West side of Uchelbeluu Reef in Palau from a depth of 240 m.
The sponge is a new species of the genus *Leiodermatium* ('Lithistid'
Demospongiae: Family Azoriciidae) presently being described. The lyophilized
sponge (730 g, dry weight) was exhaustively extracted with methanol to give 1 L
of crude extract. Roughly half of the methanol was removed *in vacuo*, and the
remaining extract was partitioned on HP20 (Supelco Diaion®) using an increasing
concentration of acetone in water as previously described. The 50% and 75%
aqueous acetone fractions exhibited the most potent activity against HCT-116 cells
and were thus purified using reversed-phase HPLC (PRP-1 semi-prep, 27.5%
acetonitrile, 2 mL/min) to give leiodelide A (1, 14 mg, 0.002% dry weight) and
leiodelide B (2, 0.8 mg, 0.0001% dry weight).

The molecular formula of leiodelide A (1) was deduced from the high
resolution MALDI-MS spectrum (598.2992, [M + Na]^+, Δ 0.9 ppm) as C_{31}H_{45}NO_{9},
which was consistent with both the ^13^C and ^1^H NMR data (Table 4.1). Analysis of
the proton (Figure 4.1) and carbon (Figure 4.2) NMR data revealed signals due to
<table>
<thead>
<tr>
<th>C#</th>
<th>$^{13}$C NMR in ppm</th>
<th>$^1$H NMR in ppm, mult. ($J$ in Hz)</th>
<th>HMBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>166.9 C</td>
<td>5.69 d (15.5)</td>
<td>C-1, C-4</td>
</tr>
<tr>
<td>2</td>
<td>124.3 CH</td>
<td>6.88 dd (15.5, 9.5)</td>
<td>C-1, C-2, C-4, C-18</td>
</tr>
<tr>
<td>3</td>
<td>151.2 CH</td>
<td>2.38 m</td>
<td>C-2, C-3, C-5, C-18</td>
</tr>
<tr>
<td>4</td>
<td>44.9 CH</td>
<td>4.54 dd (9.5, 3.0)</td>
<td>C-3, C-4, C-6, C-7, C-18</td>
</tr>
<tr>
<td>5</td>
<td>72.3 CH</td>
<td>6.31 dd (9.0, 1.0)</td>
<td>C-4, C-7, C-8, C-19</td>
</tr>
<tr>
<td>7</td>
<td>125.6 C</td>
<td>7.66 s</td>
<td>C-6, C-8, C-10</td>
</tr>
<tr>
<td>8</td>
<td>143.5 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>135.0 CH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>166.3 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>25.2 CH2</td>
<td>2.71 m</td>
<td>C-10, C-12, C-13</td>
</tr>
<tr>
<td></td>
<td>CH2</td>
<td>2.83 m</td>
<td>C-10, C-12, C-13</td>
</tr>
<tr>
<td>12</td>
<td>34.6 CH2</td>
<td>1.60 m</td>
<td>C-10, C-11, C-13, C-14, C-20</td>
</tr>
<tr>
<td></td>
<td>CH2</td>
<td>2.05 m</td>
<td>C-10, C-11, C-13, C-14, C-20</td>
</tr>
<tr>
<td>13</td>
<td>29.5 CH</td>
<td>1.28 m</td>
<td>C-11, C-12, C-14, C-15, C-20</td>
</tr>
<tr>
<td>14</td>
<td>35.9 CH2</td>
<td>1.62 m</td>
<td>C-12, C-13, C-15, C-16, C-20</td>
</tr>
<tr>
<td>15</td>
<td>80.3 CH</td>
<td>3.22 ddd (9.5, 4.5, 0.5)</td>
<td>C-13, C-14, C-21</td>
</tr>
<tr>
<td>16</td>
<td>73.1 CH</td>
<td>3.45 d (9.5)</td>
<td>C-17, C-22</td>
</tr>
<tr>
<td>17</td>
<td>70.8 CH</td>
<td>5.75 t (9.5)</td>
<td>C-1, C-15, C-16, C-22, C-23</td>
</tr>
<tr>
<td>18</td>
<td>16.8 CH3</td>
<td>1.25 d (7.0)</td>
<td>C-3, C-4, C-5</td>
</tr>
<tr>
<td>19</td>
<td>13.8 CH3</td>
<td>1.92 d (1.0)</td>
<td>C-4, C-5, C-6, C-7, C-8</td>
</tr>
<tr>
<td>20</td>
<td>21.5 CH3</td>
<td>0.97 d (6.5)</td>
<td>C-13, C-14</td>
</tr>
<tr>
<td>21</td>
<td>58.1 CH3</td>
<td>3.38 s</td>
<td>C-15</td>
</tr>
<tr>
<td>22</td>
<td>123.1 CH</td>
<td>5.14 dd (9.5, 1.0)</td>
<td>C-16, C-24, C-30</td>
</tr>
<tr>
<td>23</td>
<td>143.5 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>38.1 CH2</td>
<td>2.75 m</td>
<td>C-22, C-23, C-25, C-26, C-30</td>
</tr>
<tr>
<td></td>
<td>CH2</td>
<td>2.81 m</td>
<td>C-22, C-23, C-25, C-26, C-30</td>
</tr>
<tr>
<td>25</td>
<td>129.5 CH</td>
<td>5.45 m</td>
<td>C-27</td>
</tr>
<tr>
<td>26</td>
<td>128.2 CH</td>
<td>5.57 m</td>
<td>C-27, C-22</td>
</tr>
<tr>
<td>27</td>
<td>39.0 CH2</td>
<td>2.30 m</td>
<td>C-25, C-26, C-28, C-29, C-31</td>
</tr>
<tr>
<td></td>
<td>CH2</td>
<td>2.48 m</td>
<td>C-25, C-26, C-28, C-31</td>
</tr>
<tr>
<td>28</td>
<td>76.5 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>182.8 C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>17.9 CH3</td>
<td>1.79 d (1.0)</td>
<td>C-22, C-23, C-24</td>
</tr>
<tr>
<td>31</td>
<td>26.7 CH3</td>
<td>1.29 s</td>
<td>C-27, C-28, C-29</td>
</tr>
</tbody>
</table>
Figure 4.1 $^1$H NMR spectrum for letolide A (1) in MeOH-$d_4$. 
Figure 4.2 13C NMR spectrum for leiodelide A (1) in MeOH-d4.
two di- and two trisubstituted double bonds, four oxymethines, a methoxy group, a saturated carboxyl acid, an $\alpha,\beta$-unsaturated ester or carboxyl acid, and possibly a small heteroaromatic ring ($\delta_H$ 7.66, $\delta_C$ 135.0, $\delta_C$ 143.5, $\delta_C$ 166.3). Combined, these data suggested that 1 was an oxygenated polyketide.

Interpretation of cross peaks from the COSY spectrum (Figure 4.3) established the connectivity between two olefinic methines, C-2 ($\delta_H$ 5.69, $\delta_C$ 124.2) and C-3 ($\delta_H$ 6.88, $\delta_C$ 151.2). A large coupling constant (15.5 Hz) between H-2 and H-3 established the $E$ configuration for this disubstituted double bond. COSY correlations revealed a linear system comprised of the $\Delta^{2,3}$ olefin, a methylated methine, C-4 ($\delta_H$ 2.38, $\delta_C$ 44.8), a methyl doublet, C-18 ($\delta_H$ 1.25, $\delta_C$ 16.8), and an oxymethine, C-5 ($\delta_H$ 4.54, $\delta_C$ 72.3). The H-5 methine resonance also showed coupling to an olefinic proton resonance at C-6 ($\delta_H$ 6.31, $\delta_C$ 131.4) of a trisubstituted double bond. Allylic coupling between H-6 and the C-19 methyl protons ($\delta_H$ 1.92, $\delta_C$ 13.8) was evident from the COSY spectrum and established the presence of these two substituents in a trisubstituted double bond. A NOESY
correlation between H-19 and H-5, combined with the lack of a NOESY correlation between H-19 and H-6, established the configuration of this double bond as $E$.

COSY correlations were also used to elucidate a linear subunit comprised of two methylenes, C-11 ($\delta_H 2.71, 2.83; \delta_C 25.3$) and C-12 ($\delta_H 1.60, 2.05; \delta_C 34.6$), a methylated methine, C-13 ($\delta_H 1.28, \delta_C 29.5$), a methyl doublet, C-20 ($\delta_H 0.97, \delta_C 21.4$), a methylene, C-14 ($\delta_H 1.62, \delta_C 35.8$), and three oxymethines, C-15 ($\delta_H 3.22, \delta_C 80.2$), C-16 ($\delta_H 3.45, \delta_C 73.3$), and C-17 ($\delta_H 5.75, \delta_C 70.7$). The downfield H-17 methine resonance was also coupled to an olefinic proton at C-22 ($\delta_H 5.14, \delta_C 123.2$), which in turn showed allylic coupling to a vinyl methyl resonance at C-30 ($\delta_H 1.79, \delta_C 17.9$). NOESY cross-peaks (H-22 and H-24, H-30 and H-25) established the $E$ configuration for $\Delta^{22,23}$. The remaining proton couplings observed in the COSY spectrum were assigned to a linear four-carbon subunit consisting of a downfield methylene, C-24 ($\delta_H 2.75, 2.81; \delta_C 38.1$), two olefinic methines, C-25 ($\delta_H 5.45, \delta_C 130.1$) and C-26 ($\delta_H 5.57, \delta_C 127.4$), and an additional methylene, C-27 ($\delta_H 2.30, 2.48; \delta_C 38.9$). Selective decoupling of the C-24 methylene protons in a homonuclear decoupling experiment (HOMODEC) revealed an 11.0 Hz coupling constant between H-25 and H-26, suggesting a Z configuration for the $\Delta^{25,26}$ olefin (Figure 4.4). Additional support for this orientation was provided by NOESY correlations between the methylene protons at C-24 and C-27.
Figure 4.3 gCOSY spectrum for leiodelide A (1) in MeOH-\textit{d}_4.
Figure 4.4 Homonuclear decoupling $^1$H NMR experiment for leiodelide A (I). Selective decoupling of the C-24 methylene protons ($\delta_H$ 2.75 and 2.81) reveals an 11.0 Hz coupling constant between H-25 and H-26. Inset shows normal (fully coupled) $^1$H NMR spectrum for comparison. Truncated portion of the molecule shown for clarity.
Long-range proton-carbon correlations observed in the HMBC spectrum (Table 4.1, Figure 4.5) provided corroborative evidence to support the three subunits deduced by analysis of the COSY spectrum (C-2 to C-6, C-11 to C-22, and C-24 to C-27). In addition, HMBC correlations were observed from the olefin protons at C-2 and C-3 to the carbonyl C-1 ($\delta_C$ 166.9), establishing this as an $\alpha,\beta$-unsaturated ester moiety. HMBC correlations suggested a link between the olefinic methyl group at C-19 and a substituted olefin carbon ($\delta_C$ 125.6) assigned as C-7. In addition, the methoxy group C-21 ($\delta_H$ 3.38, $\delta_C$ 58.1) was shown to be attached to the C-15 oxymethine. An HMBC correlation from the olefinic methyl protons of C-30 to the substituted olefin carbon C-23 and the methylene C-24 established a link between C-24 and the $\Delta^{22,23}$ trisubstituted double bond.

The presence of a disubstituted 1,3-oxazole was revealed by the NMR signals at C-8 ($\delta_C$ 143.5), C-9 ($\delta_H$ 7.66, $\delta_C$ 135.0), and C-10 ($\delta_C$ 166.3), along with a characteristic $^1J_{C,H}$ value for C-9 (205.8 Hz). The heteroaromatic proton resonance H-9 exhibited long-range coupling to the quaternary carbons C-8 and C-10. HMBC correlations were observed from both H-6 and Me-19 to C-8, and from the methylene protons at C-11 and C-12 to C-10, which established the location of the oxazole moiety as shown.

An analysis of the NMR and IR spectra indicated that the remaining portion of the molecule consisted of an oxygenated quaternary carbon, C-28 ($\delta_C$
Figure 4.5 gHMBC spectrum for leiodelide A (1) in MeOH-$d_4$.\[\text{Figure 4.5}\]
76.1), a methyl singlet, C-31 (δ_H 1.29, δ_C 26.4), and an aliphatic carboxyl acid carbon, C-29 (δ_C 180.1; IR 1715 cm⁻¹). HMBC correlations (H-27 to C-28, C-29, and C-31; H-31 to C-27, C-28, C-29) established a link between the C-27 methylene and this terminal group. With all other atoms in compound 1 already accounted for, the molecular formula only allowed for an additional three carbons, five protons, and three oxygen atoms in this functional group. Taken together, these data established the unusual α-hydroxy-α-methyl carboxylic acid terminal moiety, which matches reported values for this type of functional group.²⁶,²⁷ Methylation of 1 with diazomethane to give compound 22 verified the presence of a carboxyl acid, providing further support for the proposed structure. The presence of an α-oxy-α,α-disubstituted acetic acid moiety has been reported for natural products such as quinic acid derivatives²⁸ and okadaic acid derivatives.²⁹ However, this is the first reported case of an α-hydroxy-α-methyl carboxylic acid positioned at the chain terminus of a macrocyclic lactone.

The molecular formula of (1) suggested the presence of a total of ten unsaturation equivalents. With all carbon connectivities accounted for, the remaining degree of unsaturation required a cyclic structure. An HMBC correlation from H-17 to the carbonyl carbon C-1 suggested an ester linkage between C-1 and C-17, thereby establishing the structure of 1 as an 18-membered macrolide.
The observation that chemical shift differences of methylene protons and
\textsuperscript{1}H-\textsuperscript{1}H coupling constants at centers throughout compound 1 were not dependent
on temperature (0-40°C) or NMR solvent (MeOH-\textit{d}_4, DMSO-\textit{d}_6) confirmed the
existence of a single predominant conformer.\textsuperscript{30} This implied that an assignment
of the relative stereochemistry for at least some of the chiral centers would be
possible from a combination of NOE and vicinal coupling constants.\textsuperscript{31} For the
most part, vicinal proton-proton ($^3J_{\text{H,H}}$) and carbon-proton ($^3J_{\text{C,H}}$) coupling
constants follow a Karplus-type equation and thus can be used for stereochemical
analysis.\textsuperscript{32} NOE correlations were detected with NOESY and selective 1D
NOESY experiments at 500 MHz. Approximate $^3J_{\text{H,H}}$ values were determined by
careful analysis of the \textsuperscript{1}H NMR spectrum along with homonuclear decoupling
experiments at 500 MHz, and a gHSQMBC\textsuperscript{33} experiment was used to determine
the $^3J_{\text{C,H}}$ values. This latter experiment can be used to calculate long-range
heteronuclear coupling constants by comparison with combined antiphase \textsuperscript{1}H
NMR spectra that are offset by the coupling constant in question (Figure 4.6,
Figure 4.7).

The relative configuration of C-2 to C-7 is shown in Figure 4.8. The
methine proton attached to C-5 appeared as a doublet of doublets with a large
vicinal coupling to H-6 (9.5 Hz) and a small vicinal coupling (3.0 Hz) to the
oxymethine H-4, suggesting that H-4 and H-5 are \textit{gauche} to one another. A large
Figure 4.6 Comparison of $^1$H NMR and gHSQMBC spectra ($J_{C18,H5}$) of 1: (a) Two antiphase $^1$H NMR spectra showing the H-5 peak horizontally shifted by the heteronuclear coupling constant between H-5 and C-18 (6.0 Hz); (b) Addition of the two shifted antiphase peaks pictured in (a); (c) Slice from the 2D gHSQMBC spectrum showing the correlation between H-5 and C-18.
Figure 4.7 Comparison of $^1$H NMR and gHSQMB spectrum ($J_{\text{C-3, H5}}$) of I: (a) Two antiphase $^1$H NMR spectra showing the H-5 peak horizontally shifted by the heteronuclear coupling constant between H-5 and C-3 (2.2 Hz); (b) Addition of the two shifted antiphase peaks pictured in (a); (c) Slice from the 2D gHSQMB spectrum showing the correlation between H-5 and C-3.
Figure 4.8 Relative stereochemistry of C-2 to C-7 in leiodelide A (1). Important NOE's are illustrated with dashed lines. Vicinal proton-carbon couplings ($^3J_{C,H}$) are indicated with solid arrows (H→C), whereas vicinal proton-proton couplings ($^3J_{H,H}$) are indicated with solid lines (H—H). Coupling constants are shown in parenthesis and given in Hertz.
vicinal coupling (6.0 Hz) between H-5 and C-18 (Figure 4.6), along with the presence of a NOE enhancement between H-5 and H-18 established the near-parallel syn relationship between these two centers, which is consistent with the observation of a smaller coupling (2.2 Hz) between H-5 and C-3 (Figure 4.7). These data, combined with the presence of a positive NOE enhancement between H-3 and H-6, established an eclipsing orientation for C-4 and C-5, with Me-18 gauche to the hydroxyl group at C-5 as shown (Figure 4.8).

An analysis of the coupling constants and NOE enhancements revealed the relative configuration of C-15 to C-17 (Figure 4.9). A large vicinal coupling (9.5 Hz) and the absence of an NOE enhancement between H-16 and H-17 established the antiperiplanar relationship for these two protons. A NOESY experiment performed in DMSO-$d_6$ revealed a NOE enhancement between H-22 and the hydroxyl proton at C-16, establishing an erythro configuration with the two oxygen functionalities (hydroxyl at C-16 and O-acyl at C-17) anti to one another. This is supported by the fact that, in threo 1,2-dioxygenated methine systems, the anti rotamer would be disfavored due to steric (C→C) and electrostatic (O→O) repulsion. An NOE enhancement between H-16 and H-22 and a small $^3J_{C,H}$ of 2.5 Hz between H-16 and C-22 indicated a dihedral angle of approximately 60° for these atoms, further supporting the proposed anti orientation of H-16 and H-17 (Figure 4.9).
Figure 4.9 Relative stereochemistry of C-15 to C-17 in leiodelide A (1). Important NOE’s are illustrated with dashed lines. Vicinal proton-carbon couplings ($\tilde{J}_{C,H}$) are indicated with solid arrows (H→C), whereas vicinal proton-proton couplings ($\tilde{J}_{H,H}$) are indicated with solid lines (H—H). Coupling constants are shown in parenthesis and given in Hertz.
A negligible coupling (0.5 Hz) between H-15 and H-16 suggested a system in which both protons are opposite the oxygen atoms. A small $^3J_{C,H}$ (2.5 Hz) observed for H-16 and C-14 indicated a gauche orientation for these atoms. NOE enhancements (H-17 to H-15 and Me-21; C-16OH to H-14 and Me-21; H$_2$-14 to H-16) established the configuration of C-15 relative to C-16, with the C-21 methoxy anti to H-16 (Figure 4.9). The relative configuration of a 1,3-methine system can be determined if the C-2 diastereotopic methylene protons can be assigned stereospecifically. Although it was possible to determine both the $^1H$ chemical shifts and the coupling constants of the C-14 methylene protons in DMSO-$d_6$, the presence of multiple NOE enhancements (H-14a to H-13, H-14b to H-13, H-14a to Me-20, and H-14b to Me-20) and intermediate vicinal coupling constants made an assignment of the C-13 stereochemistry relative to C-15 via C-14 difficult. Nonetheless, strong transannular NOE enhancements from H-15 to the C-12 and C-11 methylene protons indicated a turn in the macrolide skeleton at C-13. On the basis of the above arguments, the relative stereochemistry of leiodelide A (1) is proposed to be $2E, 4R^*, 5S^*, 6E, 15R^*, 16S^*, 17R, 22E, 25Z$. All vicinal coupling constants ($^3J_{H,H}$ and $^3J_{C,H}$) and NOE correlations are consistent with this configurational assignment in a single conformation.

The EIMS spectrum of leiodelide B (2) exhibited peaks of equal intensity at $m/z$ 654/656, suggesting the presence of bromine (Figure 4.10). The molecular formula of C$_{31}$H$_{44}^{79}$BrNO$_9$ was deduced by high resolution MALDI-MS.
(676.2074, [M + Na]+, Δ -2.7 ppm). The spectral data of 2 suggested that it was a related analog of 1 (Table 4.2). Detailed examination of the 1H and 13C NMR data revealed that certain portions of the molecule (C-1 to C-14; C-23 to C-28) were fundamentally conserved, while other centers were altered (Table 4.2, Figure 4.11). In particular, the oxymethines C-16 (δc 80.5) and C-17 (δc 78.4) were shifted downfield and the multiplicities of H-16 and H-17 were noticeably modified in 2. In addition, the C-22 methine (δH 4.28, δc 56.2) appeared to be brominated, while the quaternary carbon at C-23 (δc 84.0) was oxygenated. The disappearance of the Δ22,23 olefin, despite the fact that 2 has the same number of double bond equivalents as 1, introduced the possibility of an additional ring system. These data, combined with chemical reasoning, suggested an ether linkage between C-16 and C-23 to form the stable five-membered tetrahydrofuran ring as shown. NOE enhancements from H-17 to Me-30 and from H-16 to H-22 established the relative configuration around the ring (Figure 4.12). Although an HMBC correlation from H-16 to C-23 through the ether linkage was not observed, the lack of long-range correlations across a furan ring has been reported,34 and can be rationalized by an unfavorable dihedral angle between these centers.

The proposed mechanism for the formation of the 16,23-ether bridge in 2 from 1 is illustrated in Figure 4.13. In an enzyme catalyzed reaction, addition of an electrophilic bromine atom to the Δ22,23 alkene results in the formation of a
Figure 4.10 Low-resolution mass spectrum for leiodelide B (2), illustrating the parent ion cluster indicative of bromine.
Table 4.2 $^{13}$C (75 MHz, MeOH-$d_4$) and $^1$H (500 MHz, MeOH-$d_4$) NMR data for 1 and 2.

<table>
<thead>
<tr>
<th>C#</th>
<th>$^{13}$C NMR (ppm)</th>
<th>$^1$H NMR (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>166.9</td>
<td>166.6</td>
</tr>
<tr>
<td>2</td>
<td>124.3</td>
<td>122.8</td>
</tr>
<tr>
<td>3</td>
<td>151.2</td>
<td>153.1</td>
</tr>
<tr>
<td>4</td>
<td>44.9</td>
<td>45.1</td>
</tr>
<tr>
<td>5</td>
<td>72.3</td>
<td>71.7</td>
</tr>
<tr>
<td>6</td>
<td>131.4</td>
<td>131.2</td>
</tr>
<tr>
<td>7</td>
<td>125.6</td>
<td>125.5</td>
</tr>
<tr>
<td>8</td>
<td>143.5</td>
<td>143.3</td>
</tr>
<tr>
<td>9</td>
<td>135.0</td>
<td>134.5&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>10</td>
<td>166.3</td>
<td>166.4</td>
</tr>
<tr>
<td>11</td>
<td>25.2</td>
<td>25.7</td>
</tr>
<tr>
<td>12</td>
<td>34.6</td>
<td>33.9</td>
</tr>
<tr>
<td>13</td>
<td>29.5</td>
<td>30.5</td>
</tr>
<tr>
<td>14</td>
<td>35.9</td>
<td>36.7</td>
</tr>
<tr>
<td>15</td>
<td>80.3</td>
<td>78.0</td>
</tr>
<tr>
<td>16</td>
<td>73.1</td>
<td>80.5</td>
</tr>
<tr>
<td>17</td>
<td>70.8</td>
<td>78.4</td>
</tr>
<tr>
<td>18</td>
<td>16.8</td>
<td>16.3</td>
</tr>
<tr>
<td>19</td>
<td>13.8</td>
<td>13.7</td>
</tr>
<tr>
<td>20</td>
<td>21.5</td>
<td>20.7</td>
</tr>
<tr>
<td>21</td>
<td>58.1</td>
<td>58.0</td>
</tr>
<tr>
<td>22</td>
<td>123.1</td>
<td>56.2</td>
</tr>
<tr>
<td>23</td>
<td>143.5</td>
<td>84.0</td>
</tr>
<tr>
<td>24</td>
<td>38.1</td>
<td>37.6</td>
</tr>
<tr>
<td>25</td>
<td>129.5</td>
<td>126.5</td>
</tr>
<tr>
<td>26</td>
<td>128.2</td>
<td>130.4</td>
</tr>
<tr>
<td>27</td>
<td>39.0</td>
<td>39.2</td>
</tr>
<tr>
<td>28</td>
<td>76.5</td>
<td>76.4</td>
</tr>
<tr>
<td>29</td>
<td>182.8</td>
<td>182.7</td>
</tr>
<tr>
<td>30</td>
<td>17.9</td>
<td>26.0</td>
</tr>
<tr>
<td>31</td>
<td>26.7</td>
<td>26.4</td>
</tr>
</tbody>
</table>

<sup>a</sup> $^{13}$C shifts assigned indirectly by gHSQC
<sup>b</sup> determined by gHMBC
Figure 4.11 Comparison of the midfield region of $^1$H NMR spectra for 1 (top) and 2 (bottom). Double-headed arrows indicate protons that are noticeably different between the two compounds. Truncated portion of compound 2 shown for clarity.
Figure 4.12 Relative stereochemistry of C-15 to C-23 in leiodelide B (2). Important NOE’s are illustrated with dashed lines. Vicinal proton-proton couplings ($^3J_{HH}$) are indicated with solid lines (H—H). Coupling constants are shown in parenthesis and given in Hertz.
Figure 4.13  Plausible mechanism for the formation of the tetrahydrofuran 16,23-ether bridge in 2 from 1. Truncated portion of the molecule shown for clarity.

reactive bromonium intermediate. The nucleophilic hydroxyl oxygen at C-16 then attacks the more highly substituted C-23 to open the bromonium ring and create the tetrahydropyran moiety. Assuming that 1 is the precursor of 2, the relative configuration of C-15 to C-17 in 2 provides additional support for the proposed orientation of these centers in 1. The rigid five-membered ring formed as a result of the 16,23-ether bridge in 2 validates the use of NOE enhancements and vicinal coupling to determine the relative configuration of C-16 and C-17 (Figure 4.12). It is encouraging that I observed the same relative orientation for these chiral centers in both 1 and 2.

The leiodelides are the first members of an unprecedented class of polyketide natural products bearing several structural features of biogenetic interest. The oxazole unit could be derived from the amino acid serine, which would indicate a mixed biosynthetic origin for these compounds. The α,α-disubstituted carboxylic acid may be formed by a Baeyer-Villiger oxidation of an
intact acetate unit followed by a dehydrogenase-catalyzed oxidation to introduce the α-hydroxyl, as has been proposed for the biosynthesis of okadaic acid.\textsuperscript{35} Although these compounds share some structural features with other lithistid metabolites such as theonezolide,\textsuperscript{36} they do not appear to be closely related biochemically. Leiodelides A and B were found to be cytotoxic to HCT-116 human tumor cells at approximately 1.4 μg/mL (2.5 μM) and 3.8 μg/mL (5.6 μM), respectively, and their biological activity is currently undergoing further evaluation using the National Cancer Institute 60-cell line assay.

The text of this chapter is, in part, a reprint of the material that has been submitted for publication in the Journal of Organic Chemistry with co-authors Patrick Colin, Michelle Kelly, and William Fenical. I was the primary researcher and author, and the co-authors listed in this publication helped direct and supervise the research, which forms the basis of this chapter.
Experimental

**Sponge Collection and Identification:** The sponge was collected from the west side of Uchelbeluu Reef, Mutremdu, Koror, Palau, Micronesia (07°16.27’N, 134°31.37’E) by Patrick L. Colin using the manned submersible *Deep Worker 2000*, on 21 March 2001, on a sand and boulder slope at a depth of 240 m. The specimen forms a convoluted mass of thin flaring folded lamellae that may form tubes, with rounded incised margins, c. 500 mm diameter, wall 2.5 mm thick. The external surface has patches of tiny (<0.5 mm diameter) ostial pits, and the inner surface is completely covered in regularly and closely distributed oscules (<0.5 mm diameter). The lamellae margin is thick and rounded, sometimes indented or incised. The texture is stony, the surface smooth and granular with low irregular horizontal ridges, internal osculiferous surface is slightly furry with brishes of projecting diactines. The colour in life is tan. The skeleton consists of thorny rhizocone desmas and fine diactinal spicules that may form a fringe. The sponge is a new species of the genus *Leiodermatium* (‘Lithistid’ Demospongiae: Family Azoricidae) presently being described. It was formerly known as *Leiodermatium pfeifferae* Carter, 1873 or *L. pfeifferae* Carter, 1873 *forma striata* Wilson, 1925. A voucher specimen has been deposited at the Natural History Museum, London, United Kingdom.

**HCT-116 Assay.** The HCT-116 cells were plated by Catherine Sincich in 96-well plates and incubated overnight at 37°C in 5% CO₂/air. Compounds were added to
the plate and serially diluted. The plate was then incubated for a further 72 h. Cell viability was assessed at the end of this period through the use of a CellTiter 96 AQ_{ueous} non-radioactive cell proliferation assay (Promega). Inhibition concentration (IC_{50}) values are interpreted from the bioreduction of MTS/PMS by living cells into a formazan product. The first step of the assay is the addition of MTS/PMS to the sample wells followed by a 3 h incubation. The quantity of the formazan product (proportional to the number of living cells) in each well was then determined using a Molecular Devices Emax microplate reader that measured the amount of 490 nm absorbance in each well, and the IC_{50} value was calculated by a SOFTMax analysis program. Etoposide (Sigma) and DMSO (solvent) were used as positive and negative controls, respectively.

**Leiodelide A (1):** a pale yellow oil; CD (MeOH) [\theta]_{233}^{23} +11.9, [\theta]_{215}^{2} -11.0; UV (MeOH) \lambda_{max} (\log \varepsilon) 224 (3.2); IR \nu_{max} (MeOH) 3400 (br), 2930, 1715, 1650, 1585, 1455, 1410, 1360, 1275, 1235, 1180, 1140, 1090, 1025, 990 cm\(^{-1}\); for \(^{1}\)H and \(^{13}\)C NMR data see Table 4.1; (+)-LREIMS m/z (rel int) 350 (35), 508 (13), 526 (15), 551 (8), 558 (55), 576 (5), 598 (100), 599 (40), 600 (8); HRMALDIMS [M + Na]\(^{+}\) m/z 598.2992 (calcd for C_{31}H_{45}NO_{9}Na, 598.2987).

**Leiodelide B (2):** a pale yellow oil; CD (MeOH) [\theta]_{234}^{23} +6.2, [\theta]_{212}^{2} -8.3; UV (MeOH) \lambda_{max} (\log \varepsilon) 221 (2.8); IR \nu_{max} (MeOH) 3400 (br), 2935, 1715, 1655, 1460, 1415, 1360, 1270, 1225, 1200, 1140, 1095, 990, 655 cm\(^{-1}\); for \(^{1}\)H and \(^{13}\)C NMR data see Table 4.2; (+)-LREIMS m/z (rel int) 557 (6), 577 (8), 598 (15), 654
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
References


